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Abstract: Influenza is an acute respiratory infection responsible for epidemics with
high impact on human health. Several statistical methods have been applied to data
collected from influenza surveillance systems (ISS) to assess the epidemic burden and
early detect it. Given the ISS reporting delays, models have recently been developed
to correct them by predicting the present situation (nowcasting) using the incomplete
information collected. Thus, three objectives were defined.
Review and classify the methods that use interrupted mortality time series to
estimate influenza excess deaths. They were classified according to the model used to
fit the time series and obtain a baseline; the influenza epidemic period estimator and
the procedure used to fit the model (iterative or non iterative). This generalization
led to the development of user friendly R-package, flubase, implementing all these
models.
Estimate influenza excess deaths in Portugal between 1980 and 2004. The sea-
sonal excess deaths average by all causes was 2,475, of those 90% occurred in the
elderly. These results suggest a similar influenza epidemics profile between Portugal
and other countries in the Northern Hemisphere, and represent the first reference to
contextualize future epidemics severity and design public health measures.
Develop a model to nowcast the influenza epidemic evolution in a weekly basis. A
non homogenous hidden Markov model (HMM) was developed to nowcast the current
week influenza-like illness (ILI) incidence rate and the probability that the influenza
activity is epidemic using as covariates an early estimate of ILI rate and the number
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of ILI cases tested positive in the previous week. Bayesian inference was used to
estimate the model parameters and nowcasted quantities. The results obtained by
application to the Portuguese ISS data, demonstrated the additional value of using a
non homogenous HMM instead of an homogenous since it improves the ISS timeliness
in 2 weeks.
Key words: influenza, epidemics, baseline, excess deaths, cyclical regression, Au-
toregressive Moving Average (ARIMA) models, hidden Markov models (HMM), non
homogenous HMM, bayesian models, Markov Chain Monte Carlo (MCMC), nowcast-
ing, surveillance.
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Resumo:
A gripe e´ uma doenc¸a respirato´ria aguda que no hemisfe´rio norte, durante o Out-
ono e Inverno, e´ responsa´vel por epidemias com considera´vel impacto nas populac¸o˜es
humanas, traduzindo-se muitas vezes em excessos de mortalidade, hospitalizac¸o˜es e
necessidades de cuidados de sau´de.
Neste contexto, teˆm sido implementados va´rios sistemas de vigilaˆncia epidemio-
lo´gica da gripe (SVG) a n´ıvel nacional e internacional com o objectivo de fornecer a`s
autoridades de sau´de informac¸a˜o para a elaborac¸a˜o de avaliac¸o˜es de risco actualizadas
que permitam uma correcta implementac¸a˜o de medidas de controlo e mitigac¸a˜o das
epidemias e suas consequeˆncias.
Com o objectivo de medir o efeito das epidemias em termos de excessos de mor-
talidade e de detectar de forma precoce o seu in´ıcio, diversos me´todos estat´ısticos
teˆm sido propostos e aplicados aos dados colhidos por estes SVG. Em relac¸a˜o a este
u´ltimo objectivo, e dado que muitos dos SVG apresentam importantes demoras no
processo de recolha, tratamento e ana´lise dos dados, com consequentes atrasos na
detecc¸a˜o das epidemias, recentemente teˆm-se desenvolvido modelos estat´ısticos que
procuram corrigir estas faltas de informac¸a˜o. Os modelos propostos procuram enta˜o
prever a situac¸a˜o epide´mica actual - nowcasting - usando a informac¸a˜o incompleta
colhida ate´ ao momento pelo SVG.
Neste enquadramento os objectivos desta tese foram: unificar numa u´nica classe
os me´todos estat´ısticos para estimar os excessos de mortalidade atribu´ıveis a` gripe,
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que sa˜o caracterizados por usarem se´ries temporais de mortalidade interrompidas;
estimar os excessos de mortalidade atribu´ıveis a` gripe durante o per´ıodo de 1980 a
2004 e contextualiza´-los na literatura cieˆntifica internacional; e desenvolver modelos
para prever a presente situac¸a˜o epide´mica da gripe (nowcast) no contexto dos sistemas
de vigilaˆncia epidemio´logica.
Os principais me´todos estat´ısticos, que recorrem a se´ries temporais da mortali-
dade interrompidas para estimar os excessos de o´bitos associados a` gripe foram re-
vistos de forma exaustiva. O objectivo foi identificar na˜o so´ as suas caracter´ısticas
comuns mas tambe´m os factores que os diferenciam. Desta ana´lise resultou uma
unificac¸a˜o dos me´todos que se caracterizou pela sua classificac¸a˜o de acordo com os
seguintes paraˆmetros: o tipo de modelo usado para ser ajustado a` se´rie temporal
interrompida e estimar a linha de base (regressa˜o c´ıclica ou ARIMA), o per´ıodo
temporal escolhido a priori usado para estimar o per´ıodo epide´mico e o procedi-
mento para ajustar o modelo a` se´rie temporal (iterativo ou na˜o iterativo). Esta
gereralizac¸a˜o e formalizac¸a˜o levou naturalmente a` construc¸a˜o de um conjunto de
rotinas de R de fa´cil utilizac¸a˜o, o pacote flubase, que pode ser descarregado de
http://cran.r-project.org/web/packages/flubase/index.html e onde esta˜o im-
plementados todos os me´todos descritos. O pacote de rotinas desenvolvido representa
tambe´m uma importante ferramenta para a avaliac¸a˜o da sensibilidade dos excessos
de o´bitos obtidos face a` variac¸a˜o do tipo de me´todo usado, pois permite obter de
forma pra´tica e ra´pida estas estimativas para diferentes combinac¸o˜es dos paraˆmetros.
Os va´rios me´todos identificados foram ainda aplicadas a 20 anos de mortalidade por
Pneumonia e Gripe em Portugal, demonstrando que, neste caso, o paraˆmetro que
maior impacto teve nas estimativas dos excessos de o´bitos foi o tipo de per´ıodo escol-
hido para estimar o per´ıodo epide´mico.
Com base nos resultados obtidos no estudo anterior seleccionou-se o me´todo es-
tat´ıstico considerado mais adequado a` estimac¸a˜o retrospectiva dos excessos de mor-
talidade associados a` gripe em Portugal. Mais espec´ıficamente foi aplicado a`s se´ries
de mortalidade estudadas o modelo ARIMA com ajustamento na˜o iterativo onde os
per´ıodos epide´micos foram estimados com base na mortalidade espec´ıfica por gripe.
Os resultados obtidos da aplicac¸a˜o do me´todo a 7 causas de morte diferentes para 8
grupos eta´rios, permitiu: estimar em 2.475 a me´dia sazonal de o´bitos associados a`s
epidemias de gripe que ocorreram no per´ıodo de 1980 a 2004, valor este que corres-
ponde a uma taxa me´dia bruta por e´poca de 24,7 por 100.000 habitantes; verificar
vque em 5 das 24 e´pocas na˜o ocorreram excessos de o´bitos associados a` gripe e que o
ma´ximo estimado foi de 8.514 o´bitos na e´poca 1998-1999. Um outro resultado impor-
tante foi que em me´dia, os excessos estimados no grupo eta´rio ≥ 65, representaram
cerca de 90% do total dos excessos. Todos os resultados obtidos sugerem ainda que
as epidemias de gripe ocorridas neste per´ıodo em Portugal tiveram, em termos gerais,
um perfil semelhante ao descrito noutros pa´ıses com clima temperado do Hemisfe´rio
Norte. Adicionalmente, poderemos ainda afirmar que as estimativas obtidas neste
estudo, representam um passo importante para estabelecer refereˆncias para avaliar
o impacto de futuras epidemias de gripe e tambe´m para delinear medidas de sau´de
pu´blica racionais para mitigar o seu efeito.
O objectivo de reduzir a demora dos SVG na detecc¸a˜o do in´ıcio do per´ıodo
epide´mico, foi atingido com a apresentac¸a˜o de um modelo que permite prever a
taxa de incideˆncia de s´ındroma gripal (SG), assim como o estado de actividade gripal
(epide´mico ou na˜o epide´mico) da pro´pria semana. Este modelo foi escolhido na famı´lia
de modelos de cadeias de Markov escondidas (HMM), porque aplicac¸o˜es anteriores,
no contexto da detecc¸a˜o de epidemias, demonstraram algum sucesso e principalmente
porque estes modelos permitem a previsa˜o simultaˆnea de duas medidas de grande in-
teresse para este trabalho - a probabilidade de se estar no per´ıodo epide´mico e a taxa
de incideˆncia de SG. Nestes modelos as probabilidades de transic¸a˜o entre estados
podem ser assumidas como contantes ou variantes no tempo, correspondendo respec-
tivamente ao modelo homoge´neo e na˜o homoge´neo. Assim, elegeu-se naturalmente o
modelo na˜o homoge´neo para atingir o objectivo definido, dado que tem a vantagem
de permitir a inclusa˜o de covaria´veis com informac¸a˜o precoce sobre a evoluc¸a˜o da
epidemia que permitem, ao mesmo tempo, modelar a varia´vel resposta, taxa de in-
cideˆncia de SG, mas tambe´m as probabilidades de transic¸a˜o entre o estado epide´mico
e o na˜o epide´mica e vice versa.
As covaria´veis escolhidas foram uma estimativa precoce da taxa de incideˆncia de SG
calculada a` sexta-feira da pro´pria semana e o nu´mero de casos de SG com resultado
laboratorial positivo para gripe na semana anterior. As estimativas dos paraˆmetros
dos modelos assim como a taxa de incideˆncia e a probabilidade de estar no estado
epide´mico foram obtidas por me´todos de infereˆncia bayesiana. Os resultados obtidos
pela aplicac¸a˜o dos modelos propostos a` informac¸a˜o recolhida pelo SVG Portugueˆs,
demonstraram a vantagem de usar um modelo de cadeias de Markov escondidas na˜o
homoge´neo em comparac¸a˜o com um modelo homoge´neo. Concretamente foi poss´ıvel
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monstrar que, no caso deste SVG, o recurso a um HMM na˜o homoge´neo reduz o
atraso na detecc¸a˜o do in´ıcio do per´ıodo epide´mico em duas semanas.
Palavras chave: influenza, epedimias, linha de base, excessos de mortalidade,
regressa˜o c´ıclica, Modelos Autoregressivos Intregados de Me´dias Mo´veis (ARIMA),
Modelo de cadeias de Markov escondidas (HMM), HMM na˜o homoge´neos, modelos
bayesianos, Markov Chain Monte Carlo (MCMC), nowcasting, vigilaˆncia.
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Notation
The following conventions are generally followed:
• Random variables by upper-case letters and observed values of these by the
corresponding lower-case letters.
• Greek letters are used to denote parameters.
• Bold symbols correspond to vector and matrix notation.
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Chapter 1
Introduction
Influenza is an acute respiratory infection that, in the temperate climates, during
Autumn and Winter, is responsible for epidemics of considerable dimension, with
attack rates that vary between 5 and 10% of the general population and with duration
of 2 to 26 weeks [1, 2].
During these epidemic periods, influenza is associated with an increase of morbid-
ity and mortality from all causes, mainly in the individuals with 65 or more years of
age. Nevertheless the burden of influenza can also be high in the younger age groups,
usually during pandemics, like 1918-19, 1957, 1967 and 2009-10 [3, 4, 5].
In Europe it is acknowledged that seasonal influenza epidemics are responsible for
an average of 40,000 deaths per season, an important increase in the need for health
services capacities and also for a big impact in the labor force given the considerable
absenteeism they originate [6]. Given the substantial impact of the influenza epi-
demics in the human populations, public health surveillance systems were established
since 1952, when the World Health Organization (WHO) launched the WHO Global
Influenza Surveillance Network. This network is based on the National Influenza Cen-
ters that collect and send biological samples from patients with influenza-like illness
(ILI) to WHO Collaborative Centers for antigenic and genetic analysis. The main
objective of this network is to recommend the content of the influenza vaccine and
serve as a global alert mechanism for an influenza virus with pandemic potential [7].
Further more, to monitor the impact of influenza epidemics in the mortality and
morbidity of the populations other systems were also implemented. Examples are:
the 122 Cities Mortality Reporting System, managed by the United States Center
1
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for Disease Control and Prevention (US CDC), that collects weekly the number of
deaths due to Pneumonia and Influenza (P&I) by age group in 122 cities of the US
[8]; the Euro-MOMO project that collects the weekly mortality from all causes in a
network of 13 European countries [9]; the European Influenza Surveillance Network
that is based on sentinel networks of general practitioners (GP) that report on a
weekly basis the ILI incidence rate [6]. All these surveillance systems have the ob-
jective of supplying to the health authorities information to perform up-to-date risk
assessments for public health action, i.e. implement measures to control and miti-
gate the epidemics impact. Generally, information provided by these systems helps
the health authorities in following the influenza epidemic evolution, week by week,
in terms of the epidemic onset, peak and end, and also in terms of its impact and
severity, measured as excess of medical consultations, hospitalizations and mortality.
For these purposes, several statistical methods have been proposed and applied to
the data collected by these surveillance systems. The reason for the first studies was
the 1918-19 influenza pandemic. To access the impact of this event, Collins SD (1957)
[10] suggested an ecological method that estimates the monthly expected mortality
rate in the absence of the influenza epidemic and subtracts the observed mortality
rates from the expected. The sum of these excesses during the epidemic period was
considered as the excess mortality attributable to the pandemic.
In fact, this rational of defining baselines that describe an indicator behavior in the
absence of public health threats has been the basis for the majority of the statistical
methods that were presented, from then to nowadays, to identify the start of a public
health event and to estimate its impact.
Another important feature of the public surveillance system, operating for several
years, is the richness of information it contains, which could allow short term fore-
casting of indicators under analysis. For some situations, this short term forecasting
is indeed a nowcasting, given that surveillance systems usually report information
with a delay of one or more weeks, and a one or two weeks forecast is, in practice, a
prediction of the current situation, i.e. a nowcasting. The application of statistical
methods to predict the present situation or the near future, can greatly contribute to
reduce the surveillance system timeliness and enhance the up-to-date epidemic risk
assessment.
On this subject some works have also been presented with relative success [11, 12],
nevertheless none has shown to be sufficiently practical to be implemented week by
3week as a new outbreak indicator of the surveillance system.
In this context, the main research objectives of this thesis are:
1. To unify in a single class the statistical methods characterized by using inter-
rupted mortality time series to estimated excess deaths attributable to influenza
epidemics, in order to describe and compare their applicability and results;
2. To estimate the excess mortality associated with the influenza epidemics oc-
curred in Portugal in the period from 1980 to 2004 and compare the results
with those from other locations;
3. To develop a statistical model to nowcast the influenza epidemic evolution.
In general, for the first objective, the research focused on the group of methods
characterized by not considering influenza activity covariates to model the mortality
baseline and by excluding from the model fitting process all the parts of the mortality
time series where there was evidence of influenza epidemics occurrence. So, to describe
this group a comprehensive review of the main proposed methods [13, 14, 15, 16, 17,
18, 19] was carried out with the aim of finding not only their unifying characteristics
but also their differences. The identified features were then used to set a general
framework that encompasses them all. Finally, to compare the methods and the
impact of each feature on the estimates of the excess deaths associated with influenza
epidemics, the different methods were applied to the time series of deaths by P&I in
Portugal from 1980 to 2004 [20].
To accomplish the second goal the method that in [20] was shown to be more
appropriate to retrospectively estimate the excess deaths attributable to influenza
epidemics was elected to be applied to the Portuguese mortality data in the period
of 1980 to 2004. So, given that the last study on the burden of influenza epidemics in
Portugal [21] was focussed only on excesses of all causes and P&I deaths for all ages
and for the elderly (≥ 65 years) in the period from 1990 to 1998, this new work [22] has
analyzed the mortality time series for 7 causes of death (all causes, cerebrovascular
disease, ischemic heart disease, diseases of the respiratory system, chronic respiratory
diseases, and pneumonia and influenza) and 8 age groups (0-4, 5-54, 55-64, 65-69,
70-74, 75-79, 80-84 and ≥ 85).
Finally, to achieve the last research objective, to nowcast the influenza epidemics
evolution, in a public health surveillance system setting, a statistical model, within
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the family of the hidden Markov models (HMM), was developed. This class of models
was chosen not only because some success in outbreak detection problems has already
been accomplished with this framework [23, 24, 25], but also because it was further
noticed that it can enable the nowcast of two important measures, simultaneous: the
probability of being in the epidemic state and the ILI incidence rate. Within the
HMM family the state transition probabilities can be assumed constant in time or
time-variant, respectively corresponding to a homogenous or non homogenous HMM.
For this work, the non homogenous model was the elected one, because it has the
advantage of allowing the inclusion of time-variant covariates with early information
on the epidemic evolution to model not only the response variable, the ILI weekly
rate, but also the state transition probabilities from the non epidemic to the epidemic
state and vice-versa. To our knowledge, this work [26] represents the first attempt to
use non homogenous HMMs in a disease surveillance problem with the objective of
early detect an outbreak and nowcast its evolution.
The thesis is organized as follows. Chapter 2 focuses on the methods used to
estimate excess deaths attributable to influenza epidemics. Hence, after an introduc-
tion to these methods (Section 2.1) and the presentation of some essential concepts
(Section 2.2) a description of the most relevant methods is made in Section 2.3. A
general framework proposed with the objective of finding a common ground between
the methods, to describe and compare them, is then given in Section 2.4. The com-
parison between the methods is exemplified by the application of all class methods to
the time series of deaths due to P&I in Portugal from 1980 to 2004 (Section 2.5). In
Section 2.6 a set of user friendly R-routines, package flubase [27], which implement
all methods is briefly presented. The main results are then discussed in Section 2.7.
The estimates of excess mortality rates associated with influenza virus circulation
in Portugal, during the period of 1980 to 2004, is presented in Chapter 3. An intro-
duction to the impact of influenza epidemics in terms of excess mortality is given in
Section 3.1. The data description is presented in Section 3.2 and the method used
to estimate the epidemic periods and the excess deaths (selected from the framework
presented in Chapter 2) are presented in Sections 3.3 and 3.4. Section 3.5 describes
the main results and the specificity analysis applied to evaluate the method robust-
ness. Finally, Section 3.6 frames the obtained estimates in the published literature
and discusses the main differences and similarities between countries, geographical
regions and population characteristics.
5In Chapter 4 the development of a non homogenous HMM to nowcast the influenza
activity in the context of a public health surveillance system is presented. Section 4.1
introduces the motivation, the question of timeliness of a public health surveillance
system and the need to have predictions of the current situation. An overview of the
HMMs and their application to the influenza surveillance problem is then given in
Section 4.2, along with the formalization of the non homogenous HMM. At Section
4.3, the data used for the application example is introduced, the Portuguese influenza
surveillance system (ISS) from week 40/2008 to week 16/2011. In Sections 4.4 and 4.5
the specific models proposed are described along with the bayesian approach for the
model parameters estimation and for nowcasting the current ILI rate and influenza
activity state. Section 4.6 details the results, both the application of the models to
the entire data set as well as the real-time nowcast of the 2010-11 influenza season.
In section 4.7 the model and results are discussed.
Finally Chapter 5 presents the main conclusions about the research objectives
and suggestions for future developments.
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Chapter 2
Time series methods for
obtaining excess mortality
attributable to influenza
epidemics1
2.1 Introduction
In the Northern Hemisphere countries, during influenza epidemic periods, a rise in
mortality from all causes is usually observed, mainly in the elderly population (aged
65 years or more) [28]. This increase can be associated with influenza epidemics since
the influenza infection might cause complications that can lead to the hospitalization
and/or death of the infected individual [36, 37]. In this context, and from a public
health point of view, the quantification of the influenza epidemics impact on the pop-
ulation and its description in terms of the dominant virus strain and level of vaccine
coverage is of the utmost importance. The measurement of influenza impact in terms
of deaths hospitalizations is never accessed by the number of deaths with influenza as
the main cause in national mortality registries because this value is usually very low,
even during the most severe epidemics. This is mainly due to the difficulty in estab-
1This Chapter is based on the paper Nunes B, Nata´rio I, Carvalho ML. Time series methods
for obtaining excess mortality attributable to influenza epidemics. Statistical Methods in Medical
Research. 2011; 20(4):331-346. Epub 2010 March 8.
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lishing a connection between a complication (pneumonia or other respiratory diseases,
circulatory system diseases, etc) and a previous or current influenza infection, due
to the lack of a laboratory confirmed diagnosis. As a consequence, the use of official
death registries, with influenza as cause to measure the influenza epidemic impact
would underestimate its real effect [28]. This has led researchers to look for reliable
methods to estimate influenza-associated deaths, using as a starting point a mortality
time series and, when available, additional information from influenza epidemiologic
surveillance systems on the seasonal epidemic characteristics. Generally, the methods
used to estimate the excess deaths attributable to the influenza epidemics follow three
steps:
1. Obtaining a baseline of the number of deaths, by a certain time unit, in the
absence of influenza epidemics;
2. Using the baseline to identify the periods where there is evidence of an excess
of deaths attributable to influenza epidemics;
3. Subtracting this baseline from the observed number of deaths, during these
periods.
In this sense, the observed excess of deaths above the baseline, when associated
with influenza epidemic periods, could, in the absence of other explainable events, be
attributed to an influenza epidemic. The state-of-the-art of the methods to estimate
the excess deaths attributable to influenza epidemics offers a large variety of different
alternatives, all applicable to identical situations and aiming essentially the same
purpose. These methods can be classified into two general methodological approaches
and, within those, they vary in a considerable number of aspects.
In the first group, the methods are based on statistical models that include in-
fluenza activity indicators as explanatory covariates. The pioneer ones [29, 30, 31] are
multiple regression models including a polynomial function of time for trend, dummy
variables for month effect to cope with seasonal variation, the monthly mean of weekly
minimum temperature and the monthly ILI incidence rate as an influenza activity
indicator. Later, [32, 33, 34] propose a Poisson regression model including, in general,
the same type of variables, except [33] that uses one influenza activity indicator by
each sub-type of influenza virus, A(H3), A(H1) and B, plus an indicator of the respi-
ratory syncytial virus activity, all considered as proportion of isolates by week. Thus,
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this type of method enable the estimation of influenza burden by sub-type taking
into account the possible simultaneous effects of other factors in mortality, like the
effect of climate and/or other respiratory infections. These methods are very exigent
in terms of external data needed and are also dependent on the accuracy of the in-
fluenza activity indicators used that are, in general, based on sentinel surveillance
systems, which are known to be sometimes influenced by external factors like holiday
periods (e.g Christmas and New Years Eve) [35].
The methods in the second group are characterized by not considering covariates
and also by excluding from the estimating process all the parts of the mortality time
series where there is evidence of influenza epidemics occurrence. This Chapter will be
focused on this second group of methods. A close analysis of this group shows several
differences among them, essentially on the type of statistical model employed (cyclical
regression [14, 15, 16, 17, 18] or Autoregressive Integrated Moving Average (ARIMA)
models [13, 19]), on the method used to build the baseline (non iterative [17, 16, 18]
or iterative [14, 15, 13, 19]) and on the choice of the periods to be excluded from
the mortality time series (epidemic periods defined using ILI surveillance systems
[14, 17, 13, 19] or fixed periods, like December to April [15, 16, 18]). All these
differences can lead to unequal influenza-associated deaths estimates. Differences
between reported estimates have been identified leading specialists into a profound
discussion without a final agreed conclusion [38, 39].
Here we were able to unify these methods in a single class, in such a way that it
allows the description and comparison of their applicability and results. This proved
to be an important step in the conceptualization of the statistical methods used to
estimate influenza-associated deaths, clarifying all the steps performed and options
taken to compute the desired estimates. This unification was also the basis to build
an R-package, the flubase, that easily estimates the influenza-associated deaths by
any of the methods in the class. This platform is quite user friendly even for those
less familiarized with the theoretical statistical developments that have led to the
results. The application of this tool could also empower other researchers to critically
analyze the differences and similarities between the estimates obtained with a variety
of method choices, allowing in this way a more comprehensive analysis of their data.
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2.2 Some essential concepts
2.2.1 Influenza epidemic period, influenza season and flu-year
An influenza epidemic is defined as the occurrence, in a specific population, of a
number of cases of influenza above what is usually expected, during a certain period
of time, referred as the epidemic period. Usually the epidemic periods are unknown
and therefore must be estimated.
The annual fixed period of time during which the influenza epidemics might occur,
starting sooner or later, with larger or smaller duration, is named influenza season.
In Portugal as in other northern hemisphere countries, this period starts in October
of each year ending in May of the next calendar year. This is the period when the
ISS are more active, as the occurrence of an influenza epidemic outside this period
has an almost null probability. Taking into account the beginning and ending of the
influenza season, a flu-year a is defined as the 52 (or 53 when the first calendar year
of the flu-year is bissextile) weeks that start at week 27 of any calendar year n and
ends at week 26 of the calendar year n+ 1.
Let Ea denote the estimate of an influenza epidemic period occurred during flu
year a (Figure 2.1). The choice of these periods is greatly dependent on the level of
information one has on the occurrence of influenza cases and on the temporal evolution
of the influenza incidence rate in the population. In fact, to obtain a correct diagnosis
of influenza, a confirmation of the influenza virus presence is necessary, procedure that
is not usually carried out. In the majority of the situations only the clinical diagnosis
are obtained, without the laboratory confirmation, and if this situation occurs the
case can only be classified as ILI.
Therefore, the information that is usually available consists on the temporal evo-
lution of the ILI incidence rates, complemented by information on the influenza virus
circulation among the population. In the majority of the developed countries this
information is collected by surveillance systems specifically designed for the effect,
that are based on a sample of individuals set under surveillance.
When this information does not exist, or it is not available, some authors [16, 18]
have set Ea as the fixed time period, enclosed in the influenza season period, that
goes from December to April of the next calendar year. Other solution is to use
the time series of mortality specific by influenza (ICD 9th Revision:487; ICD 10th
Revision:J9-J11) and define Ea as the periods where the mortality by influenza rises
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above the expected. In principle, given the under registration of deaths with influenza
as a cause, this last option should be a less sensible but more specific method, for the
reasons we have mentioned earlier.
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Figure 2.1: Exemplification of the basic concepts.
2.2.2 Time series of the weekly number of deaths
Consider yt,a to be the time series of the number of deaths observed in week t,
t = 1(27), ..., 52(26)2 of flu-year a, a = 1, ..., A, where A represents the number of flu-
years in study. This time series is the main object of analysis, since the major goal is
to estimate from it the excess number of deaths attributable to influenza epidemics.
Usually the most used time series is the weekly (or monthly) number (or rate) of
deaths by all causes or P&I.
2The values in brackets represent year calendar week numbers
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2.2.3 Periods with excess deaths attributable to influenza epidemic
Define Da as the period of weeks where an excess of deaths in yt,a is attributed to
an influenza epidemic, in flu-year a. This period, included in the Ea period, is defined
by an observed increase in yt,a, above the expected in the absence of the effect of an
influenza epidemics (Figure 2.1). Additionally, during this period, there must be no
other events that can be the cause of the observed excess deaths.
2.2.4 Mortality baseline in the absence of the influenza epidemics
effect
Excluding from the time series the parts where there is some evidence of an influenza
epidemic occurrence, one obtain the following interrupted time series, denoted here-
after by y?t,a = {yt,a : (t, a)/∈ Ea}.
Let βt,a be the baseline (Figure 2.1) resulting from fitting a statistical model to
the time series y?t,a or, as some authors have considered, to xt,a, the weekly number
of deaths in the absence of the influenza epidemics, defined as follows:
xt,a =
{
yt,a, (t, a) 6∈ Da;
y˜t,a, (t, a) ∈ Da
(2.1)
where y˜t,a represents some preliminary estimate of the weekly number of deaths in
the absence of the effect of an influenza epidemics for the week t of the flu-year a.
2.3 Description of methods in study
The studied methods are all characterized by obtaining a mortality baseline in the
absence of influenza epidemics effects using an interrupted mortality time series. Gen-
erally these methods fit a statistical model to y?t,a to obtain a baseline βt,a that is used
to identify the periods with excess deaths attributable to an influenza epidemic, Da.
To be able to jointly describe all these procedures one has to identify the unifying
characteristics and also their differences in order to summarize them in a few classes.
Three sources of dissimilarity were found.
1. Statistical model used to fit the interrupted time series: There are
mainly two types of models used in the literature:
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(a) multiple linear regression models [14, 15, 16, 17, 18], using a polynomial
component to explain the series trend and a sinusoidal component that
captures the seasonality observed - cyclical regression. Generally these
models are given by:
ys = α+
m∑
i=1
ais
i +
l∑
j=1
b1,j sin
j2pis
52
+ b2,j cos
j2pis
52
+ εs
where ai, i = 1, ...,m, are the parameters of the order m polynomial
function used to explain the trend, b1,j and b2,j are the parameters of
the sinusoidal function with periods 52/j, j = 1, ..., l, used to explain the
eventual seasonality and εs ∼ N(0, σ
2) with s = t+ (a− 1)52, t = 1, ..., 52
and a = 1, ..., A.
(b) seasonal ARIMA[40] only applied in [13, 19] to this problem.
2. Choice of the Ea periods: In some of the reviewed papers this period was
the epidemic period defined (estimated) by the operating ISS, using data on
clinical diagnosis of ILI and viral strains isolates [14, 17, 13]. In this case the a
priori chosen Ea periods are different from flu-year to flu-year.
Other authors [15, 16, 18] defined Ea as a fixed set of weeks (December to April),
in each flu-year, where the occurrence of an influenza epidemic with effects on
mortality is more likely. This period is always included in the influenza season.
3. Procedure used to fit the statistical model and to identify the Da
periods
(a) Non iterative (Figure 2.2): the model is fitted to all points of the inter-
rupted time series y?t,a [16, 17, 18] at once. Here the baseline βt,a corre-
sponds to the estimated values given by the model for each week t. In [17]
the Da periods are defined as the set of weeks, contained in the Ea periods,
that initiate with two consecutive weeks with a number of deaths above the
upper 95% confidence limit of the baseline and end with two consecutive
weeks with a number of deaths bellow the same upper limit. Note that
[16, 18] have defined the Da periods applying the previous method only to
the mortality time series specific for influenza.
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Figure 2.2: Non iterative procedure used to fit the statistical model and to identify
the Da periods. Grey boxes represent the Ea periods and yellow boxes represent the
Da.
(b) Iterative (Figure 2.3): generally, these methods consist in forecasting a
baseline for each flu-year i using a statistical model fitted to xt,a for a
training set of T previous flu-years. This training set can have a fixed
dimension T (equal for all iterations, e.g. 5 years) [14, 15], or be given by all
previous years of flu-year i of that iteration [13]. In the iterative methods,
Di is identified in each iteration i as the period of weeks contained in the
correspondent Ei period that initiates with two consecutive weeks with a
number of deaths above the upper 95% confidence limit of the forecasted
baseline and terminate with two consecutive weeks with number of deaths
bellow the same upper limit. After the Di identification the series xt,a is
updated. Here [13] update xt,a by substituting its values in the Di periods
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by the values of the forecasted baseline, obtaining a preliminary estimate
of the mortality time series in the absence of influenza epidemic y˜t,a during
those periods. Other authors simply use an interrupted time series where
the values in the Di periods are excluded from the original time series.
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Figure 2.3: Iterative procedure used to fit the statistical model and to identify the
Da period. Grey boxes represent the Ea periods and yellow boxes represent the Da.
2.4 General framework
Given the above description it is possible to accommodate a large number of meth-
ods in a wide framework of methods varying according to the three points considered,
model fitting procedure, type of model and period where to identify the excess mor-
tality periods attributable to the influenza epidemics Da - see Table 2.1.
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Name Alias Model Period Fitting procedure T
It_RM_F [15] Regression Fixed period Iterative 5
It_RM_E [14] Regression ISS Iterative 5
It_SA_F none SARIMA Fixed period Iterative all previous years
It_SA_E [13] SARIMA ISS Iterative all previous years
RM_F [18, 16] Regression Fixed period Non iterative NA
RM_E [17] Regression ISS Non iterative NA
SA_F none SARIMA Fixed period Non iterative NA
SA_E none SARIMA ISS Non iterative NA
Table 2.1: Classification of the proposed methods for comparison, according to the
fitting procedure (iterative or not), the model (seasonal ARIMA or cyclic regression)
and the Ea periods (fixed period or a period estimated by the national Influenza
Surveillance Systems, ISS). T represents the dimension of the training set.
Note that it was possible to further identify three new methods, never considered
before, from taking all possible combinations of alternatives:
1. It_SA_F iterative, using the the seasonal ARIMA model with Ea periods fixed;
2. SA_F and SA_E that apply the seasonal ARIMA models with a non iterative
procedure.
The It_SA_F does not seem to present any practical application problems. For
methods SA_F and SA_E we propose to adjust a cyclic regression model to the inter-
rupted time series, substitute then the Ea periods by the model expectations, and
then apply the seasonal ARIMA models to this new series.
In order to be able to compare all the methods described in Table 2.1 we had to
address the following difficulties:
1. Evaluation of the adjustment quality of the baseline βt,a to the original time
series yt,a for (t, a) /∈ Da. Given that the objective is to estimate a baseline free
of excess mortality, the model is not fitted to the observed data during these
Da periods. This condition makes unfeasible the direct application of the more
used goodness of fit measures (AIC, BIC, etc.), since the Da periods and the
resulting baseline differ from method to method. To overcome this we have
considered the following measures for the baseline outside the Da:
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• Residual Mean Square
RMS =
∑
(t,a)/∈Da
eˆ2t,a
m
where m is the number of weeks without excess deaths attributable to
influenza eˆt,a = yt,a − βt,a for (t, a) /∈ Da;
• Autocorrelation function of the residuals;
2. The true number of excess deaths attributable to influenza epidemics for each
flu-year a is unknown. Therefore, the evaluation of the methods considering
their excess deaths estimates was accomplished by:
• comparing, in each flu-year a, the estimated excess deaths attributable
to influenza epidemics given by each method, and identifying those that
estimate the higher and lower values of excess deaths;
• calculating the correlation between the estimates of the influenza excess
deaths, obtained by different methods, as an empirical concordance mea-
sure.
2.5 Application example
The analyzed data consists on the weekly number of deaths by P&I in Portugal from
1980-81 to 2003-04 flu-years obtained from the National Mortality database of the
Portuguese Statistics Institute (Figure 2.4).
As presented in Table 2.2 the Ea periods were either set as fixed periods (from
week 48 (December) to week 17 (April)) or equal to the non fixed epidemic periods
that were defined as follows:
• From 1980-81 to 1989-90 the influenza epidemic periods were defined using the
weekly number of deaths by influenza (ICD 9th Revision 487). These periods
were set as the consecutive weeks (more than two) with the number of deaths
above the 95 percentile of the empirical distribution of the weekly number of
deaths by influenza in the period comprised by the flu-years 1980-81 to 1989-90;
• For the flu-years from 1990-91 to 2003-04 the epidemic periods used were
the ones defined by the Portuguese ISS, of the Instituto Nacional de Sau´de
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Figure 2.4: Distribution of the weekly number of deaths by influenza and pneumonia
in Portugal from 1980-81 to 2003-04.
Dr.Ricardo Jorge (of National Health Institute Dr. Ricardo Jorge) [41]. The
final classification is presented in Table 2.2.
In this time series we have also substituted the known heat-waves periods [42] by
the average of the number of deaths in the last week before and the first week after
the heat-wave.
The models used in the application example were chosen in the following way:
1. The cyclic models used were chosen by a regular best fit model criteria, in a
preliminar analysis.
• non iterative procedure:
ys = α+ β1s+ β2s
2 + β3s
3 + b1 sin
2pis
52
+ b2 cos
2pis
52
+ εs
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Epidemic periods (weeks)
flu-year start peak end no weeks max incidence
1980-81 49 3 12 16 NA
1981-82 - - - - NA
1982-83 1 2 7 7 NA
1983-84 10 11 12 3 NA
1984-85 3 3 4 2 NA
1985-86 52 3 3 4 NA
1986-87 - - - - NA
1987-88 - - - - NA
1988-89 - - - - NA
1989-90 1 3 6 6 NA
1990-91 7 9 11 5 148.4
1991-92 45 52 5 13 92.4
1992-93 6 11 14 9 117.7
1993-94 46 49 1 8 168.8
1994-95 3 5 8 6 84.1
1995-96 42 44 51 10 86.8
1996-97 47 50 8 15 111.3
1997-98 - - - - -
1998-99 51 3 8 10 252.9
1999-00 2 5 8 7 156.5
2000-01 - - - - -
2001-02 1 5 10 10 239
2002-03 48 50 50 3 76.1
2003-04 44 47 52 9 166.7
Table 2.2: Definition of the epidemic periods Ea for the flu-years 1980-81 to 2003-04
(NA: not available). Incidence values are presented by 105 inhabitants. From 1980-81
to 1989-90 epidemic periods were defined by the influenza death cause criterium, from
1990-91 to 2003-04 the epidemic periods were defined by the Influenza Surveillance
System.
• iterative procedure:
ys = α+ β1s+ β2s
2 + b1 sin
2pis
52
+ b2 cos
2pis
52
+ εs
2. The seasonal ARIMA models used were:
• non iterative procedure: chosen by an automatic model identification al-
gorithm [43];
• iterative procedure: a model analogous to the one proposed in [13],
ARIMA(2, 0, 0)(1, 1, 0)52 :
(1− φ1B − φ1B
2)(1− Φ1B
52)∇52ys = εs,
where s = t+ (a− 1)52; t = 1, ..., 52; a = 1, ..., 24; εs ∼ N(0, σ
2).
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In the present application example the Da periods were always defined as the set
of weeks, contained in the Ea periods, that initiate with two weeks with a number
of deaths by P&I above the upper 95% confidence limit of the baseline and end with
two weeks with a number of deaths bellow the same upper limit.
2.5.1 Results
The methods that considered the Ea periods as fixed presented lower RMS than the
methods using year-variable size periods, estimated by the ISS. Within each of these
two different groups (fixed period or ISS periods) it was observed that the seasonal
ARIMA model always presented lower values of RMS when compared to the cyclic
regression model – Figure 2.5. Autocorrelation in the residuals outside of the Da
periods was observed for all the methods that used cyclic regression models.
RM_F SA_F It_RM_F It_SA_F RM_E SA_E It_RM_E It_SA_E
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Figure 2.5: Residual Mean Square Errors of the studied models.
From Figures 2.6 and 2.7 it can be observed that when the Ea period is set fixed,
the number of influenza-associated estimated deaths is clearly higher. On the other
hand, when the Ea periods are set by the ISS it is patent an higher uniformity in
the number of influenza-associated estimated deaths, between the methods. This
observation was confirmed by the high correlation coefficients obtained between all
methods for those using Ea defined by the ISS, that as can be seen in Table 2.3 are all
above 0.95. Analyzing the results produced by the iterative approach one can identify
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a greater disagreement between estimates after flu year 1993-1994 mainly when the
Ea period was fixed.
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Figure 2.6: Estimated influenza-associated deaths from 1980-81 to 2003-2004 accord-
ing to the type of method, considering Ea as a fixed period from week 48 (December)
to week 17 (April).
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RM_F SA_F It_RM_F It_SA_F RM_E SA_E It_RM_E It_SA_E
RM_F 1 0.996 0.935 0.909 0.952 0.938 0.914 0.909
SA_F - 1 0.933 0.914 0.961 0.946 0.917 0.915
It_RM_F - - 1 0.793 0.924 0.926 0.932 0.915
It_SA_F - - - 1 0.885 0.872 0.831 0.854
RM_E - - - - 1 0.996 0.975 0.979
SA_E - - - - - 1 0.984 0.986
It_RM_E - - - - - - 1 0.976
I_SA_E - - - - - - - 1
Table 2.3: Correlation between the estimates of the influenza excess deaths, obtained
by different methods.
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Figure 2.7: Estimated influenza-associated deaths from 1980-81 to 2003-2004 accord-
ing to the type of method, considering Ea as defined by the Influenza Surveillance
System.
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2.6 The R-package flubase
The R-package flubase [27] is a set of functions designed to estimate a mortality,
or other indicator, baseline free of influenza epidemics, or other time defined event,
and the respective attributable excesses for one or more time series (e.g. age groups,
gender, regions, etc). The methods available in flubase are the ones described in
section 2.4, namely:
1. non iterative with baseline estimated by a cyclical regression (RM_F and RM_E)
implemented in the function: baseRM;
2. non iterative with baseline estimated by ARIMA models (SA_F and SA_E) im-
plemented in the function: baseSA;
3. iterative with baseline forecasted by a cyclical regression (It_RM_F and It_RM_E)
implemented in the function: baseIt_RM;
4. iterative with baseline forecasted by ARIMA models (It_SA_F and It_SA_E)
implemented in the function: baseIt_SA.
Additionally to the specific methods functions it was also implemented a general
function:
flubase(dat, groups, per, pe = 0, method, indicator=mortality, g_label)
where,
• dat: a data.frame with all the variables needed: dat$group indicating the group to
each time series belongs, dat$year indicating the civil year, dat$todeath is the time
unit index that can be week or month, dat$nod are the number of deaths observed at
each time and dat$epi is an indicator variable of the epidemic period (dat$epi=1 if
the week or month belongs to the epidemic period and dat$epi=0 otherwise);
• groups: number of groups considered, e.g. number of age groups, regions, etc.;
• per: parameter that defines if data is weekly (per = 52) or monthly (per = 12);
• pe: parameter that states if the user will provide the epidemic periods or uses fixed
periods. pe = 0 if the user provides the epidemic periods in the epi parameter; other-
wise, pe = 1 if the function uses a fixed period from week 47 to week 17 or from month
12 to month 4;
• method: the method used to estimate the baseline, method=c(”nrm”,”nsa”,”irm”,”isa”).
nrm: non iterative multiple regression, nsa: non iterative seasonal ARIMA, irm: iter-
ative multiple regression and isa: iterative seasonal ARIMA;
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• indicator: a text string indicating the name of the indicator. By default indica-
tor=”mortality”;
• g_label: a vector string whose length is the number of groups, containing the labels
for the groups, e.g. g_label = c(male”, ”female”)” or g_label = c(0−14yrs”, ”15−
44yrs”, ”45− 64yrs”, ”65 + yrs”)”.
This function can apply any of the framework methods to a pre-prepared data
set dat producing a text file with the vectors, beta0, the baseline vectors, beta_up,
the upper 95% confidence limit of the baseline and, da, a vector of 0 and 1s indicat-
ing the weeks or months with excess deaths attributable to an influenza epidemic.
Additionally flubase produces a graph showing the observed number of deaths, the
baseline, the respective upper 95% confidence interval, the epidemic periods and the
periods with excess deaths attributable to influenza epidemics, in grey and yellow
boxes respectively.
2.6.1 Example
For illustrative purposes consider the time series of weekly number of deaths by all
causes for Portugal in the period from 1997 to 2004.
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Figure 2.8: Weekly number of deaths from all causes in Portugal for the period from
1997 to 2004
So, in order to estimate excess deaths associated with influenza epidemics using
the flubase package, the following situations are presented:
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• Ea periods as fixed and the non iterative procedure with a cyclical regression
model (Figure 2.9 and Table 2.4) >flubase(data, groups=1, per=52, pe = 1,
method="nrm", indicator = "mortality", g_label="all causes").
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Figure 2.9: Output of flubase package considering Ea periods as fixed and the non
iterative procedure with a cyclical regression model. Blue line is the observed number
of deaths, black line is the baseline, red line is the upper 95% confidence limit for the
baseline, grey boxes are the Ea periods, yellow boxes are the Da periods.
Event Observed Expected Excess
1 - - -
2 30,410 21,016 9,394
3 16,910 12,681 4,229
4 - - -
5 18,933 15,165 3,768
6 5,135 4,399 736
7 - - -
Table 2.4: Output of flubase: excess deaths estimates for each Ea period, considering
Ea periods as fixed and the non iterative procedure with cyclical regression model.
26
2. Time series methods for obtaining excess mortality attributable to influenza
epidemics
• Ea periods provided by the user and the non iterative procedure with a seasonal
ARIMA model (Figure 2.10 and Table 2.5) >flubase(data, groups=1, per=52,
pe = 0, method="nsa", indicator = "mortality", g_label="all causes")
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Figure 2.10: Output of flubase package considering Ea periods provided by the
user and the non iterative procedure with a seasonal ARIMA model. Blue line is
the observed number of deaths, black line is the baseline, red line is the upper 95%
confidence limit for the baseline, grey boxes are the Ea periods, yellow boxes are the
Da periods
Event Observed Expected Excess
1 32,815 24,244 8,571
2 19,254 15,100 4,154
3 23,851 19,956 38,95
4 - - -
5 21,820 19,298 2,522
Table 2.5: Output of the flubase: excess deaths estimates for each Ea period, Ea
periods provided by the user and the non iterative procedure with a seasonal ARIMA
model.
As presented before the methods implemented in flubase were developed for the
purpose of estimating excess deaths attributable to influenza epidemics. Nonetheless
given the generality of the propose, the mortality indicator can be replaced by other
indicators, like hospitalizations, medical consultations, drug sales, etc. On the other
hand, we can go even further on this generalization by considering other events with
impact on mortality or other indicators.
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As can be seen in Figure 2.8 there is a high peak of mortality during the summer
of 2003. This excess of mortality was already shown to be associated with a heat-
wave occurred from 30 July to 15 August 2003 [44]. So if one wanted to use flubase
package to estimate this observed excess one would need to set the weeks where the
heat-wave occurred as an Ea period. In this approach the Ea periods are generalized
to a period where an event (epidemic, environmental, etc) with potential impact on
the indicator of interest (deaths, hospitalizations, consultations, etc) has occurred. In
this context, after setting the weeks of the heat-wave as 1 in the data file used in the
previous example one can the call flubase function as follows (see results in Figure
2.11 and Table 2.6):
>flubase(data, groups=1, per=52, pe = 0, method="nrm", indicator = "mortality",
g_label="all causes")
m
o
rta
lit
y
Observed mortality and model baseline for group all causes
1998 1999 2000 2001 2002 2003 2004
0
30
0
60
0
90
0
13
00
17
00
21
00
25
00
29
00
33
00
Figure 2.11: Output of flubase package considering Ea periods provided by the
user (including the 2003 heat-wave) and the non iterative procedure with a cyclical
regression model. Blue line is the observed number of deaths, black line is the baseline,
red line is the upper 95% confidence limit for the baseline, grey boxes are the Ea
periods, yellow boxes are the Da periods
As can be seen from Table 2.6 the flubase estimated an excess of 2,665 deaths
attributable to the 2003 heat-wave, using the non interactive cyclical regression model.
This estimate do not greatly differ from the previously published estimates [44] that
vary from 1,884 to 2,229, obtained with other methods and with daily data.
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Event Observed Expected Excess
1 30,410 22,126 8,284
2 14,473 11,131 3,342
3 18,933 15,822 3,111
4 - - -
5 7,804 5,139 2,665
6 14,827 12,877 1,950
Table 2.6: Excess deaths estimates for each Ea period (including the 2003 heat-wave),
Ea periods provided by the user and the non iterative procedure with a cyclical
regression model.
2.7 Discussion
The present work constitutes an important step towards a unified analysis of the
methods that use interrupted mortality time series to estimate death associated with
influenza epidemics. This was achievement via the identification of the principal
similarities and differences between the main existing methods, leading to the defi-
nition of a methodological class and a subsequent parametrization of its members in
terms of the type of statistical model, the a priori chosen type of period to estimate
the epidemic period and the procedure employed to fit the model to the interrupted
mortality time series and identify the periods with excess deaths associated to in-
fluenza epidemics. It is also important to notice that using this very broad structure
three new methods, never considered before, were identified and proposed: iterative
approach with seasonal ARIMA model considering Ea periods as fixed and the non-
iterative approach using the seasonal ARIMA model considering Ea periods as fixed
or as estimated from an external data source.
Additionally, another important output of this parametrization is a set of R-
routines, package flubase. These user friendly routines, downloadable at
http://cran.r-project.org/web/packages/flubase/index.html [27], constitute
an important tool for the estimation of the influenza associated deaths, as one can
easily compare the results obtained by varying each one of the parameters involved.
Further, this package can also be used to estimate excesses of deaths or of other in-
dicators, attributable to other events defined in time and with potential impact on
the indicator of interest. For instance the non iterative cyclical regression model was
already applied with success to estimate excess deaths attributable to heat-waves
[45, 46]. In this case, the Ea period was set as the number of weeks where the
heat-wave occurred.
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Pelat et al [47] have also developed a tool that is able to automatically obtain a
baseline and quantify the excess of deaths attributable to influenza allowing the user
to vary some parameters. Nevertheless, they have only included cyclical regression
models and have not made comparisons between the results obtained with the different
methodological approaches.
We must mention that not all the differences between methods were parameter-
ized. One that was not considered was the possible replacement of the values in the
interrupted periods of the time series by the corresponding forecasts obtained from a
training set period. Note that here, we have not replaced the values in the interrupted
periods when the model chosen was the cyclic regression one but, when the model
was the ARIMA, we have substitute them by previous years forecasts, in accordance
with the original paper where they have been proposed. This option was taken for
simplicity sake.
We note that, in the following discussion, the comparisons between methods are
only supported by a single application, the weekly number of deaths by P&I in Portu-
gal. In our opinion, this fact does not pose a problem as the inconsistencies observed
in the results between methods are enough to question the idea that they all produce
equivalent results.
As mentioned before, for comparing methods the main question is not which one
will produce the best results. Since the true number of influenza associated deaths
is unknown we have to rely on relative comparisons of results between methods and
associated class parameters.
In this sense, we have observed that the most sensitive parameter was the type of
a priori chosen Ea period. As should be expected, the higher estimates were obtained
when this period was set fixed from December to April. Intuitively, one can say that
this type of period is more sensitive and that the one defined by the ISS gives a more
specific estimate but also more conservative. In our opinion, this parameter is the
cornerstone in establishing the epidemiological association between the occurrence
of influenza epidemics and the simultaneous observation of excess of deaths in the
mortality time series. We have further obtained a lower RMS when the Ea period
was fixed, which can be explained by the fact that in this situation a great part of the
remaining time series belongs to spring and summer where the observations variation
is lower.
Considering the type of model fitted we have seen that the seasonal ARIMA
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model presents always lower RMS than the cyclic regression model and also non
autocorrelated residuals off the Da periods. The main consequence of these results is
a lower upper 95% confidence limit for the methods using seasonal ARIMA models.
This gain in efficiency has been also reported in other works [13].
The baseline building process also seems to be a parameter with important impact
on the estimates. In this application we have seen that the estimates from the iterative
procedure differ from the estimates of the non-iterative procedure essentially after
the 1993-94 flu-year. From Figure 2.4 we can see that this is the moment when the
time series presents an important change in trend. Generally speaking, the iterative
processes are more likely to produce estimates further apart from the observed values
than the estimates obtained by fitting the model directly to the entire time series,
because these methods only use data from previous flu-years to estimate each flu-year
baseline. This is more evident where, as it happens in here, the iterations are made
with weekly observations for an entire year ahead. In fact, the first proposals of the
iterative approach in the literature were not to be applied to this problem but to
build baselines for surveillance purposes [13, 48], that makes all the sense since the
next flu-year data was not yet observed. To be true, this is the method used in the
actual mortality surveillance systems [8, 9, 45].
Chapter 3
Excess mortality associated with
influenza epidemics in Portugal,
1980 to 20041
3.1 Introduction
As referred previously, seasonal influenza epidemics have a substantial mortality and
morbidity impact on human health globally [49, 50, 51]. In the US the most recent
estimates, provided by the CDC, for the period from 1976 to 2007, point to a seasonal
average of 23,607 deaths ranging from 3,349 in 1986-87 to 48,614 in 2003-04 [55]. For
Europe the European Center for Prevention and Disease Control (ECDC) considers
that the overall seasonal influenza epidemics burden is about 40,000 deaths [6].
The exact burden of influenza is difficult to quantify because laboratory tests are
rarely conducted on a routine basis. Further, influenza can trigger secondary bacterial
infections or exacerbate existing chronic conditions, which can lead to hospitalization
or death, even after the primary viral infection has been cleared. As a result, as it
was discussed in Chapter 2, influenza disease burden studies rely on the application of
statistical time series methods to broadly-defined disease outcomes, such as mortality
and hospitalization from P&I or respiratory and cardiovascular diseases, or all-cause
mortality to estimate the excesses attributable to the influenza epidemics [16, 33, 52,
53, 54].
1This Chapter is based on the paper Nunes B, Viboud C, Machado A,
Ringholz C, Rebelo-de-Andrade H, et al. (2011) Excess Mortality Associated
with Influenza Epidemics in Portugal, 1980 to 2004. PLoS ONE 6(6): e20661.
doi:10.1371/journal.pone.0020661
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A substantial body of evidence suggests that age is one of the most important
risk factors when considering the health impact of influenza. Children under 5 years
and adults of 65 years and older are considered to be at an increased level of risk for
influenza-related complications during inter-pandemic periods [33, 56]. Several stud-
ies have explored the influenza-associated rates of hospitalization and death among
seniors in the US, Canada, and Europe, as well as in a few high-income tropical
settings [18, 34, 57, 58, 59].
Very little information, however, is available for Southern Europe, with only one
mortality study set in Italy [18]. In particular, no estimates for Portugal exist in the
English-speaking literature, and the ones available corresponds to all causes mortality
outcome for all ages and for the elderly (≥ 65 years) in the period from 1990 to 1998.
In this study the authors estimated a seasonal average of 1,774 deaths attributable
to influenza epidemics raging from 806 to 3,979 [21].
Given this lack of knowledge for Portugal and for the South of Europe regard-
ing the influenza epidemic burden, its this study aim to provide estimates of excess
mortality associated with influenza virus activity in Portugal by death category (cere-
brovascular disease, ischemic heart disease, diseases of the respiratory system, chronic
respiratory diseases, and pneumonia and influenza), age group (0-4, 5-54, 65-69, 70-
74, 75-79, 80-84 and ≥ 85), and circulating virus subtypes for 1980-2004 and compare
our estimates with those from other locations.
3.2 Data
3.2.1 Mortality and population data
Mortality data available for 1980-2004 were obtained from the Portuguese National
Mortality Database of the Instituto Nacional de Estat´ıstica (National Statistics In-
stitute in Portugal). The 9th revision of the WHO International Classification of
Diseases (ICD-9) was used until 2001, and the 10th revision (ICD-10) was used there-
after. Mortality time series data were compiled monthly according to age group (0-4,
5-54, 55-64, 65-69, 70-74, 75-79, 80-84 and ≥ 85 years) for all-cause mortality and the
following primary causes of death: cerebrovascular disease (ICD-9: 430-438, ICD-10:
I60.0-I69.8); ischemic heart disease (ICD-9: 410-414, ICD-10: I20.0-I25.9); diseases
of the respiratory system (ICD-9: 460-519, ICD-10: J00-J99); chronic respiratory
diseases, including bronchitis, asthma, and emphysema (ICD-9: 490-495 and ICD-10:
3.2. Data 33
J41-J47); pneumonia (ICD-9: 480-486, ICD-10: J12.0-J18.9) and influenza (ICD-9:
487, ICD-10: J10.0-J11.8).
To evaluate the specificity of our approach, we also studied deaths from inten-
tional and non-intentional injuries (ICD-9, E-codes and ICD-10, codes V-Y), which
we considered as a ”control” outcome with no direct causal association with influenza
activity.
In order to cover influenza epidemic seasons, which can occur from October to
May in Portugal, 24 respiratory seasons were defined starting in July of the first
available year (1980) and ending in June of the last available year (2004).
So, for each of these causes of death, let us consider yt,a,g the number of observed
deaths for month t = 1, ..., 12, flu-year a = 1(1980/81), ..., 24(2003/04) and age g =
1(0−4), ..., 8(≥ 65). Age-specific annual population estimates from 1980 to 2004 were
downloaded from the Instituto Nacional de Estat´ıstica website (http://www.ine.pt)
[60] and used to derive monthly death rates by disease outcome and age group. Ad-
ditionally, all monthly time series were standardized to a fixed number of days in
the month (30.4 days) and the time series of the mortality rates per inhabitant were
calculated:
rt,a,g =
yt,a,g
Na,g
30.4
mt
were mt represents the number of days of month t and Na,g the total population
estimate in flu-year a and age group g.
3.2.2 Influenza-like illness and virological surveillance data
An integrated clinical, epidemiological and virological influenza surveillance system
was established in Portugal in the winter of 1990-1991. Data on ILI, as defined in
primary care [61], were collected by a network of Sentinel GP’s (Me´dicos-Sentinela)
which total patient list represents approximately 2.3% of the Portuguese population.
Weekly ILI incidence rates were calculated based on these data. A subset of 25-
35% of GPs also provided respiratory specimens to conduct virological surveillance.
Respiratory specimens were centralized at the Centro Nacional da Gripe (National
Influenza Centre) of Instituto Nacional de Sau´de Dr. Ricardo Jorge in Lisbon and
tested for influenza A/H3N2, A/H1N1 and B subtypes by PCR or culture. Influenza
subtype dominance each season was defined as the subtype that was isolated in at
least 51% of the influenza-positive ILI cases.
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3.3 Definition of epidemic periods Ea
For most of the study period, 1980-81 to 2001-02, influenza epidemic periods Ea were
estimated based on monthly deaths for all ages coded specifically as influenza, which is
considered a specific indicator of the timing of epidemics [16, 18]. We used a Serfling
[48] like approach i.e. a non interactive cyclical regression model with Ea periods
fixed (December to April) to predict baseline mortality in the absence of influenza
epidemics and define epidemic periods, as in [16, 18]. The model included time trends
and seasonal terms as following:
ys = α+ a1s+ a2s
2 + a3s
3 + b1 sin
2pis
52
+ b2 cos
2pis
52
+ εs
where s is a running index for time s = t + (a − 1)12 for month t = 1, ..., 12 and
flu-year a = 1, ..., 24; ys is the number of influenza-specific deaths in month s; α is
the intercept; ai are coefficients for time trends in baseline mortality; b1 and b2 are
seasonality coefficients; and εs represents normally distributed errors.
The estimates of the epidemic periods Ea were then defined as the set of consecu-
tive months from November to April where the observed number of influenza-specific
deaths exceeds the 95% upper confidence limit of the model baseline [16, 18].
Following the transition from the 9th to the 10th revision of ICD in 2002, influenza-
specific mortality decreased dramatically, and influenza epidemic periods could not
be defined based on these data alone. For the remaining seasons 2002-2004, epidemic
periods were defined by the Portuguese ISS as the weeks where ILI incidence rate ex-
ceeded the upper 95% confidence limit of the ILI baseline and where influenza virus
circulation was confirmed by laboratory tests, as in [62]. Since mortality data were
available on a monthly basis, we considered a given month to be epidemic if at least
one week during that month was considered epidemic in the ISS. We also checked
the consistency of using influenza-specific deaths and ILI incidence to estimate the
Ea periods, based on the subset of years when both types of data were available
(1991-2002).
3.4 Estimation of influenza-associated excess deaths
In order to estimate the excess deaths associated with influenza epidemics in Portu-
gal for each age group and death outcome (pneumonia, chronic respiratory diseases,
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all respiratory diseases, cerebrovascular diseases, ischemic heart diseases) one of the
methods from the general framework described in section 2.4 was chosen. Hence, in
the context of the results obtained in Chapter 2 the seasonal ARIMA model with
a non iterative fitting procedure (for details please see Section 2.4) and Ea periods
estimated as described in previous section was the selected method. This decision
was based on the fact that 1. Seasonal ARIMA models are more efficient in han-
dling time series with auto-correlation, 2. The non iterative procedure is the most
adequate to retrospectively estimate influenza-associated excess deaths and 3. using
Ea periods estimated from external sources of data is a more conservative approach
which is more appropriate given the ecologic nature of this study.
The chosen method was then applied to the natural logarithm of death rates
zt,a,g = ln(rt,a,g). This data transformation was performed in order to stabilize the
time series variance.
In order to evaluate model adequacy, we computed the Box-Ljung test for auto-
correlation and the Kolmogorov-Smirnov test for normality of model residuals outside
of epidemic periods.
The obtained baseline and the respective upper 95% confidence limit of the log-
death rates were then exponentiated to estimate the Da,g periods, i.e. the periods
with excess death rates attributable to influenza epidemics for each flu-year a and age
group g. More specifically the baseline of the death rates in the absence of influenza
epidemics and the respective upper 95% confidence limit were calculated by:
βˆrt,a,g = exp (βˆ
z
t,a,g)
u(βˆrt,a,g) = exp (βˆ
z
t,a,g + p0.975σˆe,g)
were βˆzt,a,g is the estimated baseline of the natural logarithm of the death rates without
the effect of the Ea periods predicted by the ARIMA model, σˆe,g is the estimated
standard deviation of the seasonal ARIMA model and p0.975 is the 97.5% percentile
of the standard normal distribution.
The Da,g periods were then estimated as the consecutive months contained in the
Ea periods where rt,a,g > u(βˆ
r
t,a,g).
For the months included in the Da,g periods the excess death rates attributable
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to influenza epidemics were then estimated as:
rext,a,g = rt,a,g − βˆ
r
t,a,g
and the absolute number of excess deaths as:
yext,a,g = r
ex
t,a,gAt,a,g,
where At,a,g =
mtNa,g
30.4 .
Given that our main aim was to estimate the total excess deaths attributable
to each occurred influenza epidemic, corresponding to each Ea period, one needs to
obtain first the total excess deaths in each Ea period for each age group:
yexa,g =
∑
(t,a)∈Da,g
yext,a,g (3.1)
and finally the total excess deaths in the Ea for all ages groups:
yexa =
8∑
g=1
yexa,g (3.2)
The excesses attributable to influenza epidemics are presented as absolute num-
bers, and as crude and age-standardized rates using the 2000 world population as a
reference [63]. They are calculated as:
rstexa =
8∑
g=1
wg
yexa,g
Na,g
(3.3)
where wg is the weight of age group g in the world population estimated for year
2000. Additionally the proportion of deaths attributable to influenza among all deaths
occurring from October to May (influenza season) is also presented, averaged across
all influenza seasons.
3.4.1 Excess deaths confidence intervals
Confidence intervals for seasonal excess death and age-standardized excess death rates
were obtained by taking into account the uncertainty of the baseline and assuming
that the sum of monthly excess deaths during epidemic periods followed a log-normal
distribution.
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In order to obtain a confidence interval for the absolute number of deaths at-
tributable to influenza epidemic Ea (y
ex
a ) we start by finding the distribution y
ex
a,g.
From equation 3.2 one can assume that:
yexa,g =
∑
(t,a)∈Da,g
(yt,a,g − βˆ
y
t,a,g)
where
βˆyt,a,g = exp(βˆ
z
t,a,g)At,a,g,
is the expected number of deaths, in the absence of influenza epidemics, for month
t flu-year a and age group g. Admitting that the observed deaths (yt,a,g) are fixed,
we only need to find the distribution of expected number of deaths according to the
baseline βˆyt,a,g.
From the ARIMA model one can consider that βˆzt,a,g ∼ N(xt,a,g, σ
2
e,g), conditional
on xt,a,g, where xt,a,g, like in equation 2.1, is the time series of the log-transformed
rates with Ea periods imputed by the predictions (z˜t,a,g) obtained from the cyclical
regression models fitted to the interrupted time series z?t,a,g = {zt,a,g : (t, a, g)/∈ Ea}:
xt,a,g =
{
zt,a,g, (t, a) 6∈ Ea
z˜t,a,g, (t, a) ∈ Ea
In this context one can assume that:
βˆyt,a,g = At,a,g exp (βˆ
z
t,a,g) ∼ Log-N(lnAt,a,g + xt,a,g, σ
2
e,g).
Given this result from the Fenton-Wilkinson approximation [64] the sum of the base-
line values for each Da,g period will also be Log-Normal:
βˆya,g =
∑
(t,a)∈Da,g
βˆya,g,t ∼ Log-N(µβya,g , σ
2
βˆya,g
)
where
σ2
βˆya,g
= ln

(exp(σ2e,g)− 1)
∑
(t,a)∈Da,g
exp (2 (ln(At,a,g) + xt,a,g))(∑
(t,a)∈Da,g
ln(At,a,g) + xt,a,g
)2 + 1


and
µβˆya,g = ln

 ∑
(t,a)∈Da,g
ln(At,a,g) + xt,a,g

+ σ2e,g
2
−
σ2
βˆya,g
2
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Finally, using also the Fenton-Wilkinson approximation, the distribution of the
expected number of deaths in the absence of the influenza epidemics effect, for all age
groups, is given by:
βˆya =
8∑
g=1
βˆya,g ∼ Log-N(µβˆya , σ
2
βˆya
)
where
σ2
βˆya
= ln


∑8
g=1 exp(2µβˆya,g + σ
2
βˆya,g
)(exp(σ2
βˆya,g
)− 1)(∑8
g=1 exp
(
2µβˆya,g +
σ2
βˆ
y
a,g
2
))2 + 1


and
µβya = ln

 8∑
g=1
exp

2µβˆya,g +
σ2
βˆya,g
2



− σ2βˆya
2
In summary the 95% confidence interval for the all ages excess deaths attributable
to the influenza epidemic Ea (y
ex
a ) was obtained by subtracting the upper 0.975 and
lower 0.025 probability quantiles of the βya distribution from the sum of observed
number of deaths for all age groups ya =
∑8
g=1
∑
(t,a)∈Da,g
yt,a,g in the Da,g periods.
Another measure of interest calculated in this work was the age-standardized
excess death rates for each Ea period. Considering that:
rstexa =
8∑
g=1
wg
Na,g
yexa,g =
=
8∑
g=1
Wg(ya,g − βˆ
y
a,g)
and assuming that
∑8
g=1Wgya,g is known we need to obtain the distribution of
βˆrsta =
∑8
g=1Wgβˆ
y
a,g, where Wg =
wg
Na,g
.
So according to the previous results:
Wgβ
y
a,g ∼ Log-N(ln(Wg) + µβˆya,g , σ
2
βya,g
)
and, from the Fenton-Wilkinson approximation the sum over all age groups:
βˆrsta ∼ Log-N(µβˆrsta
, σ2
βˆrsta
)
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where
σ2
βˆrsta
= ln


∑8
g=1 exp
(
2 ln(Wg) + µβˆya,g + σ
2
βˆya,g
)
(exp(σ2
βˆya,g
)− 1)(∑8
g=1 exp
(
2 ln(Wg) + µβˆya,g +
σ2
βˆ
y
a,g
2
))2 + 1


and
µβˆrsta
= ln

 8∑
g=1
exp

2 ln(Wg) + µβˆya,g +
σ2
βˆya,g
2



− σ2βˆrsta
2
To finalize the 95% confidence interval for rstexa is obtained by subtracting the up-
per 0.975 and lower 0.025 probability quantiles of βˆrsta distribution from
∑8
g=1Wgya,g.
All results were computed in the R Environment for Statistical Computing [28].
3.5 Results
3.5.1 Overall burden of influenza
Portugal experiences highly seasonal influenza activity concentrated in winter months,
with peaks in influenza-specific mortality occurring between December and March.
As in other developed countries, the impact of influenza epidemics varies greatly
between years, as illustrated by important year-to-year variation in the size of P&I
and all-cause mortality peaks (Figure 3.1).
During the study period, 1980-2004, the seasonal average number of all cause
excess deaths associated with influenza epidemics was 2,475 in Portugal (range=0
to 8,514), 90% of which occurred in people aged ≥ 65 years, representing a crude
excess all-cause death rate of 24.7 per 100,000. The corresponding average age-
standardized rate was 13 per 100,000 inhabitants, representing an average of 3%
of total deaths occurring between October and May (range 0 to 9.2%, Table 3.1).
In seniors aged 65 years and over, the average age-standardized excess death rate
during these months was 156 per 100,000 inhabitants, representing 4% of all October-
May deaths in this age group (range 0 to 11.9%). For cerebrovascular and ischemic
heart disease outcomes, the average age-standardized death rate were 2.9 and 0.7 per
100,000, respectively, representing averages of 3.2% and 2% of the age-standardized
mortality rate for those causes during the influenza season (Table 3.2). The age-
standardized mortality rates was 3.1/100,000 for respiratory diseases, 1.5/100,000 for
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P&I, and 0.8/100,000 for chronic respiratory diseases. Influenza was responsible for
9.9%, 9.3% and 6.9% on average of all deaths from P&I causes, respiratory diseases,
and chronic respiratory diseases, respectively. Similar results were observed for the
elderly (≥ 65 years) (Table 3.2). We estimate than on average 662 respiratory deaths
are attributable to influenza every season in Portugal, of which 44% are coded as P&I.
3.5.2 Age-specific estimates
The distribution of age-specific all-cause excess mortality rates followed a J-shape,
with highest rates in seniors over 65 years, and the 0-4 age group experiencing higher
excess mortality rates than individuals aged 5-54 years (Table 3.2 and Figure 3.2). In
children under 5 years, no excess deaths could be attributed to influenza in chronic
respiratory diseases, ischemic heart diseases or cerebrovascular diseases. There were
very few deaths coded as such in this age group. Excess mortality rates increased
exponentially with age for age groups over 55 years. This pattern was also observed
for excess mortality from P&I and chronic respiratory diseases but not for the other
causes of death studied. Interestingly, the J-shape almost disappeared when exploring
the age-specific proportion of October-May deaths attributable to influenza, which
instead demonstrated a near linear association with age (Figure 3.2). This suggests
that measuring the proportion of excess deaths due to influenza is a good way to
standardize burden estimates across age groups (and possibly across time and geog-
raphy).
3.5.3 Burden of influenza according to season and dominant sub-
type
Of the 24 influenza seasons studied, 14 were dominated by the more severe A/H3N2
subtype (Table 3.1). Average excess mortality rates were 3.3-6.1 higher for seasons
dominated by A(H3) viruses compared to seasons dominated by influenza B or A(H1),
depending on the outcome studied (Table 3.2). Seasons associated with the highest
excess mortality rates (e.g, 1998-99 and 1980-81) had an especially high disease burden
in people aged ≥ 65 years. Five of the 24 seasons were associated with no excess death
in any of the studied causes.
3
.5
.
R
esu
lts
41
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
5
0
1
5
0
A. All causes of mortality
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
1
5
3
0
B. Cerobrovascular diseases
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
4
8
C. Ischemic heart disease
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
1
0
2
0
D. Diseases of the respiratory system
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
4
8
E. Pneumonia and influenza
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
2
4
6
F. Chronic respiratory diseases
Year
M
o
r
t
a
l
i
t
y
 
r
a
t
e
1980 1985 1990 1995 2000 2005
0
4
8
G. Injuries
Figure 3.1: All age mortality rates for A. All causes, B. Cerebrovascular diseases, C. Ischemic heart diseases, D. Diseases of the
respiratory system, E. Pneumonia and Influenza, F. Chronic respiratory diseases and G. injuries from 1980/81 to 2003/2004
in Portugal. Grey highlights represent influenza epidemic periods.
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Season
Epidemic
Periods
based on
ISS
Epidemic
Periods
based on
ISM
Number of
epidemic
months
ISM
Dominant
virus
(sub)type**
All causes
influenza
-associated
deaths 95% CI
All causes
influenza
-associated
deaths rates
per 100,000
population 95% CI
1980-1981 - 12-3 4 A(H3N2) 5,638 5,044 - 6,232 39.1 34.7 – 43.6
1981-1982 - 1-2 2 B 0 - 0.0 -
1983-1984 - 3-4 1 A(H1N1) 2,487 2,053 - 2,901 15.7 12.7 – 18.8
1984-1985 - 1-2 2 A(H3N2) 1,802 1,468 - 2,136 12.0 9.7 – 14.4
1985-1986 - 12-2 3 A(H3N2) 4,784 4,193 - 5,375 28.4 24.6 – 32.1
1986-1987 - 1 1 A(H1N1) 1,202 861 - 1,543 6.7 4.7 – 8.7
1987-1988 - 1 1 B, A(H1N1) 0 - 0.0 -
1988-1989 - 12-1 2
A(H1N1),
A(H3N2) 2,530 2,053 - 3,007 13.7 11.0 – 16.4
1989-1990 - 1-2 2 A(H3N2) 3,920 3,516 - 4,324 19.7 17.6 – 21.6
1990-1991 - 12-2 3 B 2,781 2,313 - 3,249 13.7 11.4 – 16.0
1991-1992 11-1 12-2 3 A(H3N2) 2,845 2,466 - 3,244 14.1 12.1 – 16.1
1992-1993 2-4 3 1 B 107 17 - 197 0.6 0.1 – 1.2
1993-1994 11-1 12-1 2 A(H3N2) 3,529 3,601 - 3,997 15.9 13.8 – 18.0
1994-1995 1-2 11 1 B 0 - 0.0 -
1995-1996 10-1 11-12 2 A(H3N2) 1,892 1,527 - 2,257 8.8 7.0 – 10.7
1996-1997 11-2 12-3 4 A(H3N2) 5,533 4,997 - 6,069 25.5 22.8 – 28.3
1997-1998 x 3-4 2 A(H3N2) 308 91 - 525 1.1 0.3 – 1.9
1998-1999 12-2 12-4 5 A(H3N2) 8,514 7,908 - 9,120 36.1 33.2 – 39.0
1999-2000 1-2 1-2 2 A(H3N2) 3,363 2,904 - 3,822 14.2 12.1 – 16.2
2000-2001 x x 0 B 0 - 0.0 -
2001-2002 1-2 1-3 3 A(H3N2) 2,145 1,722 - 2,568 8.8 6.9 – 10.8
2002-2003 11-12 11-12* 2 B 0 - 0.0 -
2003-2004 10-12 10-12* 2 A(H3N2) 950 656 - 1,244 3.1 2.1 – 4.1
Table 3.1: Characterization of influenza seasons from 1980-1981 to 2003-2004 according to the duration of the epidemic
periods, dominant (sub)type of influenza virus, all causes influenza associated excess absolute deaths and age-standardized
death rates. ISS: Influenza surveillance system, ISM: Influenza specific mortality. * Information is based on ILI surveillance
and influenza virus activity; x - no epidemic period detected; NA, data not available.; Month numbers 1-January to 12-
December ** Information on the season dominant type of virus for seasons 1982-83 to 1989-90 was obtained from the WHO.
From 1990-91 to 2004-05 this information was obtained by the Portuguese ISS.
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All Causes
Cerebrovascular
diseases
Ischemic
heart
disease
Diseases of
the respiratory
system
Pneumonia
and Influenza
Chronic
respiratory
diseases
Rate %IS Rate %IS Rate %IS Rate %IS Rate %IS Rate %IS
All individuals 12.97 3.0 2.88 3.2 0.69 2.0 3.14 9.3 1.45 9.90 0.77 6.9
Individuals ≥ 65 155.75 4.00 38.48 3.50 8.19 2.30 35.69 10.1 16.86 11.6 9.09 10.00
Age group
0-4 2.57 1.3 *** *** *** *** 0.40 2.5 0.7 6.0 *** ***
5-54 0.97 0.80 0.08 1.20 0.07 1.10 0.4 8.1 0.20 7.2 0.1 4.1
55-64 14.2 2.00 1.02 1.10 0.93 1.20 4.0 9.8 1.0 7.7 1.0 5.3
65-69 34.96 2.60 4.51 1.7 3.49 2.20 11.50 11.80 3.5 12.0 5.0 10.7
70-74 78.80 3.4 19.19 3.3 3.5 1.3 18.9 10.0 6.2 10.3 5.6 6.5
75-79 170.7 4.2 41.85 3.5 10.4 2.5 37.2 10.4 14.8 11.3 10.7 7.3
80-84 332.3 4.6 96.50 4.3 17.4 2.8 74.7 11.2 40.9 14.3 14.4 6.3
≥ 85 825.8 5.5 207.10 4.8 33.5 3.2 174.2 11.8 103.5 14.1 33.6 8.9
Dominant virus*
A(H3) 18.0 4.2 3.8 4.3 1.0 2.8 4.5 13.4 2.1 13.9 1.1 9.9
A(H1) or B 4.1 0.9 1.2 1.3 0.1 0.4 0.7 2.1 0.4 2.9 0.2 1.7
Ratio A(H3)/A(H1) or B 4.4 4.5 3.1 3.4 6.8 7.5 6.8 6.56 5.5 4.8 5.0 5.7
p** 0.001 0.001 0.015 0.004 0.001 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.001 < 0.001
Table 3.2: Average rates of excess mortality associated with influenza epidemics and proportion of deaths attributable to
influenza by disease outcome, age group, and dominant viral subtype, Portugal 1980-2004. Rates are per 100,000 population.
* age-standardized rates; % IS: proportion of winter death attributable to influenza; calculated as the ratio of excess deaths
to death occurring from October to May, by age group, mortality outcome, and season; ** Mann-Whitney test for comparison
of excess mortality during A(H3) and A(H1) or B seasons; *** data not presented due to small death counts
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Figure 3.2: Age-specific influenza excess mortality burden. Average rates (per 100,000 persons) and proportion of winter
mortality associated with influenza epidemics from 1980-1981 to 2003-2004 by age group: A. All causes, B. Cerebrovascular
diseases, C. Ischemic heart diseases, D. Diseases of the respiratory system, E. Pneumonia and Influenza, F. Chronic respiratory
diseases.(* data not presented due to low annual number of deaths). The proportion of winter mortality attributable to
influenza was calculated as the ratio of seasonal excess mortality to mortality occurring during Oct to Mar, for each disease
outcome and age group.
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3.5.4 Comparison of influenza-related excess mortality and morbid-
ity
We compared seasonal excess mortality patterns in seniors over 65 years old (which
account for the majority of influenza-related deaths) with morbidity patterns in ILI
consultation rates in the same age group. The correlation between age-standardized
influenza-associated mortality rates for the studied causes and seasonal ILI consulta-
tion rates ranged between 0.64 and 0.83 (p < 0.05; Table 3.3). These results show
that high ILI seasons were associated high excess mortality seasons among seniors.
In Figure 3.3 we present the results for P&I.
All causes CVD IHD DRS PI CRD ILI(1) Injuries
All causes 1 0.950* 0.845* 0.926* 0.950* 0.824* 0.765* 0.026
CVD 1 0.783* 0.786* 0.857* 0.652* 0.641* -0.082
IHD 1 0.855* 0.828* 0.806* 0.829* 0.094
DRS 1 0.952* 0.949* 0.807* 0.079
PI 1 0.838* 0.743* -0.0002
CRD 1 0.794* 0.151
ILI(1) 1 0.426
Table 3.3: Correlation matrix between seasonal age-standardized excess rates. In-
juries are used as a control time series which should not be associated with influenza
virus circulation. CVD: cardiovascular disease; IHD: ischemic heart disease; DRS:
diseases of the respiratory system: PI: Pneumonia and Influenza; CRD chronic respi-
ratory disease: * p < 0.05; (1) correlation with ILI was only performed for the group
of 65 and plus years of age.
3.5.5 Influenza epidemic periods validation and model diagnostics
We used two approaches to define epidemic periods; one was based on influenza-
specific deaths and the other on the Portuguese ISS, combining ILI and influenza
laboratory surveillance. The two approaches proved to be consistent in the period
when both datasets overlapped, 1991-2002 (Table 3.1). There was a lag of 0 to 1
months between epidemic periods defined by the Surveillance System and influenza-
specific mortality, except for the mild 1994-1995 season, where epidemic periods did
not match.
Model fit was relatively good as there was no auto-correlation in the residuals of
the SARIMA models in 46 out of the 48 models; however, normality of the residuals
was always rejected (See details in Appendix A). Seasonal excess mortality estimates
were generally consistent across the various causes of death studied (correlation range,
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Figure 3.3: Seasonal rates of excess pneumonia and influenza and seasonal rates of
influenza like illnesses in the elderly population over 65 years, showing dominant
circulation strains of virus.
0.65 to 0.95, p < 0.05; Table 3.3). In particular the correlation between all-causes
excess deaths and excess P&I deaths was very high 0.95 (p < 0.001).
3.5.6 Specificity analysis
Next, we applied the same excess mortality approach to deaths from injuries, to
check that the method did not spuriously attribute deaths to influenza in unrelated
outcomes. The seasonality of injuries was out-of-phase with that of influenza and
displayed summer peaks (Figure 3.1). On average for the 24 seasons under study,
our excess mortality approach attributed only 0.66% of all injury deaths to influenza
(See details in Appendix B), which is much lower than our estimates for other studied
causes of death (2-10%, Table 3.2).
In addition, seasonal age-standardized excess mortality rates from injuries were
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not correlated with excess rates from causes that are traditionally associated with
influenza (p > 0.05 for correlation with excess deaths from P&I, chronic respiratory
diseases; all respiratory diseases; cardiovascular disease; ischemic heart disease; all-
causes; Table 3.3). Finally, there was no correlation between seasonal excess deaths
from injuries and seasonal ILI attack rates in seniors.
3.6 Discussion
This is the first study to provide estimates of influenza seasonal mortality burden for
the Portuguese population in a comprehensive way, which is an important step for
designing rational national public health measures and in comparing rates with other
countries. On average, 2,475 excess all-cause deaths were attributable to influenza
in Portugal each winter during 1980-2004 (range=0 to 8,514), corresponding to a
seasonal excess mortality rate of 24.7 per 100,000, and a 2000 world population age-
adjusted rate of 13 per 100,000.
Our estimates of influenza-related excess mortality rate are in accordance with
previous studies. In the US, Thompson et al. estimated an average excess mortality
rate of 19.6 per 100,000 inhabitants [33], while Schanzer et al.[58] calculated that
influenza was responsible for an excess mortality rate of 13.0 per 100,000 in Canada.
In Europe, excess mortality rates varied between 16.0 per 100,000 in Germany [17]
and 26.0 per 100,000 in the Czech Republic [54].
Despite the fact that P&I and all-cause excess mortality are considered reliable
indicators of influenza mortality impact [33, 15], here we used a broader approach
and evaluated the impact of influenza epidemics on various causes of mortality in
Portugal [49]. Although excess mortality was observed for 7 causes of death that
are traditionally linked to influenza, in this study, the highest proportion of October-
May deaths attributable to influenza was observed for respiratory-related illnesses,
with proportions ranging between 6.9 and 9.9%. Since influenza can precipitate other
severe respiratory conditions, a higher influenza attributable proportion is expected
for respiratory diseases, especially for pneumonia [65]. Similar results were obtained
in Canada [58] and the US [16, 33], where pneumonia had the highest estimated
percentage (8%) of deaths attributable to influenza. By contrast, all-cause mortality
is a less specific outcome and we estimate that only 3% of total October-May deaths in
Portugal can be attributable to influenza (4% in seniors over 65 years). This compares
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with estimates of 5% in the US [16] and 4.8% in Italy [18]. We note there is substantial
inter-annual variation in this percentage in Portugal and in other countries [16, 18],
as the burden of influenza epidemics varies considerably depending on circulating
strains and population immunity.
It is interesting to note that P&I excess deaths only captured on average 11.2%
of the total mortality burden of influenza in Portugal. By contrast, excess cere-
brovascular mortality was the major contributor to total influenza-associated deaths
(22.3%). This is not entirely unexpected, as cerebrovascular disease is the primary
cause of death in Portugal [66]. For comparison, estimates obtained in Canada show
that the proportion of excess deaths captured by P&I was 22.7% (8% for influenza
and 14.7% for pneumonia), while cerebrovascular disease only contributed to 6.5% of
influenza-attributable deaths [58]. The major contributor to influenza excess mortal-
ity in Canada was P&I and ischemic heart disease, the latter outcome representing
22.9% of all influenza-associated deaths. This finding is particularly relevant be-
cause ischemic heart disease is the leading cause of death in Canada [67]. Whether
between-country differences in leading causes of deaths and their association with
influenza result from differences in coding practices or health status remains unclear
and warrants further studies.
Overall, the selection of the most appropriate cause of death to adequately mea-
sure the burden of influenza remains a point of debate. On the one hand, the usage
of influenza-specific deaths grossly underestimates the actual impact of the influenza
virus [28]. For example, in this study, the ratio of all influenza-attributable deaths to
deaths coded specifically as influenza reached 23, and the number of influenza-coded
deaths declined dramatically after 2002, in parallel with the transition of WHO Inter-
national Classification of Diseases from revision 9 to 10. On the other hand, all-cause
mortality lacks specificity and provides less accurate estimates, especially for milder
seasons [33]. As reviewed in [49] and [68], the causal relationship between influenza
and cardiovascular disease is well established, so that mortality from cardiovascular
diseases should be more systematically included in influenza mortality studies.
Seasons with highest estimates of excess deaths were characterized by a dominance
of the A(H3) influenza viral subtype in Portugal, a pattern that was consistent across
all mortality outcomes. A higher level of hospitalizations and deaths associated with
the A(H3) subtype is already well documented [16, 33, 17]. In our study, influenza B
seasons had generally very low impact. In particular, the 5 seasons associated with no
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excess mortality were dominated by influenza B or had high proportion of B viruses.
Influenza B is generally more prevalent in children and young adults, who have lower
risk of severe influenza-related outcomes than seniors.
The age-standardized ratio of A(H3) vs (A(H1) or B) excess mortality was re-
spectively 4.8 and 3.6 for P&I and all causes in Portuguese seniors. Similar results
have been obtained in Italy for P&I (4.5) [18]. By contrast, the subtype rate ratio for
all-cause mortality was much lower, in the US (2.8) and in Italy (2.9), after taking
into account population age differences [16, 18]. These divergences could be explained
by differences in the strength and sampling protocols of laboratory virus surveillance
systems in each country and/or the definition of subtype-dominant seasons.
On average, 90% of influenza-associated excess deaths occurred in the 65 years
age group. Studies in the Netherlands [32] and the US [33] estimated that 90-95% of
influenza-related deaths occurred in seniors despite the use of a different methodolog-
ical approach and time periods. In Portugal, the unadjusted rate of all-cause excess
mortality was 165 per 100,000 on average in people 65 years. This value was 12-65%
higher than estimates for Italy [18], Netherlands [32], US [16], and Canada [58]. One
possible explanation for these differences could be the lower level of influenza vac-
cine coverage in Portuguese seniors compared to these countries. From 1998/99 to
2003/04, the influenza vaccine coverage in the elderly increased from 31% to 47% in
Portugal [69]. While this progress is significant, these values were considerably lower
than coverage estimates in the other countries over comparable time periods. For
instance, seasonal influenza vaccine coverage increased from 32% in 1993/94 to 61%
in 2000/2001 in Italy [18] and from 31% in 1988/89 to 65% in 2000/2001 in the US
[16]. We note that no decline in influenza attributable excess mortality was observed
in Italy and the US as vaccination coverage increased [16, 18], suggesting that vac-
cination is not the only explanation for the higher excess mortality rates observed
among Portuguese seniors.
The average excess mortality rate for the children aged 0-4 years old in this study
was 2.6/100,000, which is an order of magnitude higher than findings from previous
studies. A recent study in the Netherlands did not find any excess mortality associated
with influenza in the younger groups during 1997-2003 [70]. Another study in the US
showed that the average influenza-associated excess death rates for children < 1 years
and 1-4 years of age were 0.3 and 0.2 per 100,000, respectively [33]. The US study also
estimated a much higher rate of excess mortality due to respiratory syncytial virus
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(RSV) in these age groups, a finding that is in line with many other studies that
establish RSV as a predominant respiratory virus in young children [71, 72, 73]. It is
possible that our estimates of influenza excess mortality for young Portuguese children
could be confounded by the co-circulation of RSV. Unfortunately, no information on
the circulation of RSV is currently available for Portugal.
In this study, we found that excess mortality increased exponentially with age
after 50 years of age, while the proportion of October-May deaths attributable to
influenza increased more linearly with age. This indicates that the increased risk of
influenza-related mortality with age is driven by the increase in background risk of
death and may even suggest that the etiological fraction of influenza does not increase
with age as much as other potential causes.
There are some caveats worth noting in our study. First, we relied on statis-
tical models based on seasonal linear regression and SARIMA to estimate by an
ecological method the burden of influenza. We have compared estimates from our
SARIMA approach with those from a traditional Serfling seasonal linear regression
[16, 48] and found very consistent results. In addition, we report a strong association
between seasonal rates of influenza like illness and excess mortality for causes that
are traditionally linked to influenza in the elderly population. This result confirms
the robustness of our estimates of influenza-attributable excess death, since indepen-
dent indicators of influenza-related excess mortality and morbidity coincide. We have
also checked the specificity of our approach by estimating excess deaths attributable
to influenza in injury mortality time series. This specificity analysis revealed that
the proportion of injury deaths ”attributable” to influenza was very low, and that
season-to-season variations in excess injuries were not associated with ILI activity.
This supports the conclusion that our approach provides excess mortality estimates
that are specific to influenza.
Chapter 4
Nowcasting influenza epidemics
using non homogenous hidden
Markov models1
4.1 Introduction
During public health threats like infectious diseases outbreaks (SARS, West Nile
virus, pandemic influenza, etc) knowing in real-time the epidemic trend, spatial dis-
tribution and impact in terms of medical consultations, hospitalizations and deaths
is essential to identify the most appropriate measures to control the disease spread
and mitigate its effect [74, 75, 76]. It is widely accepted that the most proper tool
to acquire reliable information on disease spread and impact remains in the use of
stable disease surveillance systems defined as “...the ongoing, systematic collection,
analysis, interpretation and dissemination of disease related data for public health
action...” [74].
As mentioned before, the epidemiological surveillance of influenza activity in Eu-
rope is supported by sentinel systems, formed by GP’s, that provide weekly the num-
ber of consultations with patients presenting ILI symptoms. These figures divided
by the number of patients in the GP list or the total number of consultations on
that week enable the estimation of ILI incidence rates. On other hand GP sentinel
networks also provide, for some of the ILI patient reported, nasopharyngeal swabs
that after laboratory confirmation support the virological surveillance of the influenza
1This Chapter was based on the paper Nunes B, Nata´rio I, Carvalho L. Nowcasting influenza
epidemics using non homogenous hidden Markov models. submitted for publication in the peered
reviewed journal Statistics in Medicine in July 2011.
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activity [6, 77].
At the European level the ISS is managed by the ECDC through a network of
countries named European Influenza Surveillance Network. In this framework each
Wednesday all participating countries upload age-specific ILI rates and virological
information corresponding to the previous week2 in a web-based system (TESSy: The
European Surveillance System). The European influenza activity report gathering
information from all the participating countries (WISO: weekly influenza surveillance
overview) is issued by the ECDC on the following Friday [6].
In a no delay reporting situation one could consider that by Monday all the
information to estimate ILI rates for the previous week should be complete. So for a
particular week t, ILI rate estimated on Monday of week t+1 could be considered the
zero day delay ILI rate estimate. Having made these considerations, in the present
European surveillance system, countries upload age-specific ILI rates with a 2 days
delay and ECDC issues the WISO with a 4 days delay.
Timeliness of a public health surveillance system is one of its most important
characteristics, given that it is crucial for its capacity of a timely intervention [74, 75].
For this study, timeliness will be considered as the time elapsed from the disease onset
to the generation of an automated alert.
The prospective detection of the beginning of the epidemic period has been done
by a variety of statistical methods such as regression techniques, time series methods,
methods of statistical process control and also on statistical multivariate analysis us-
ing multiple data sources. A comprehensive review of these methods can be found
in [78, 79, 80, 81]. Some of these methods were implemented in the R package
surveillance [82] and can be easily used for ongoing disease surveillance. Neverthe-
less, for all these methods the main goal is to identify the first week of the epidemic
period, when the ILI incidence rate indicates levels of influenza activity that can be
classified as epidemic.
Regarding the ISS based on GP sentinel networks, all these methods were only
applied to data referring to the previous week. This means that the online detection
algorithms could only report an alert at most by the beginning of the following week.
Despite that, data providers (GP) send the data to the surveillance system on a
daily basis. This has became more promptly since some surveillance systems use
web-based systems where GP can enter data during consultation with the patient
2ISO definition: Monday through Sunday
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[83] or use computer routines to capture data from GP electronic medical records
[84, 85]. Therefore this daily data stream could provide the surveillance systems
sufficient information to assess the current situation, without time delay, enabling
the real-time early detection of the epidemic start, peak and end.
The process of predicting the present situation using the available incomplete
information has been considered of high interest by public health officials, mainly
during the pandemic (H1N1)2009 receiving the term of nowcasting [86]. The use
of incomplete information was already applied to nowcast on a weekly basis, the
number of influenza A(H1N1)2009 hospitalizations during the 2009-10 pandemic in
the Netherlands with considerable success [12].
In this work we developed a statistic model that on a weekly basis, uses all data
collected by a surveillance system before the end of the week, to nowcast two mea-
sures of interest: the ILI incidence rate and the influenza activity state, epidemic or
non-epidemic, that will be reported by Wednesday of the following week to ECDC.
Given this objective, we were able to show the adding value of using a non homoge-
nous HMM, being the advantage mainly shown by its ability of using covariates, with
early information on the epidemic (like weekly ILI cases laboratory confirmed, early
estimates of the ILI rate, ILI rate for other age groups, etc), to model time vary-
ing influenza activity state transition probabilities, in opposition to the homogenous
model used in prior studies [23, 24, 25], where the state transition probabilities remain
constant overtime. Additionally we were also capable of introducing covariates in the
response variable (Wednesday ILI rate) in order to nowcast its specific value. To
our knowledge this work represents the first attempt to use non homogenous HMMs
in a disease surveillance problem with the objective of early detect an outbreak and
nowcast its evolution.
4.2 Hidden Markov models
4.2.1 Model specification
Generally a HMM assumes that an observed time series, yt with t = 1, 2, ..., is a
realization of a stochastic process {Yt : t = 1, 2, ...}, where the distribution of each
Yt is conditionally determined by an unobserved (hidden) discrete Markov process
{St : t = 1, 2, ...}, taking values in a m-states set {1, 2, ...,m}.
This unobserved stochastic process is assumed to be, in the most usual form, an
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Figure 4.1: Direct graph of an order one HMM
order one homogenous Markov chain, with initial distribution P (S1 = i) and state
transition probabilities given by γj,i = P (St = i|St−1 = j) for any i, j ∈ {1, ...,m},
the elements of the transition probabilities matrix Γ = (γj,i).
In this model Yt is considered to be a state dependent process, which means that
when St is known, the distribution of Yt is determined by its value. As a consequence
Yt conditionally on St is independent from its previous observations and previous
hidden states (Figure 4.1). More specifically the state dependent distributions are:
fi(Yt = y|St = i, θ i)
with i ∈ {1, ...,m} and t = 1, 2, ..., where fi represents the state i specific density (or
mass) function of Yt with parameters θi.
Given this considerations the likelihood of an observed time series yT = (y1, ..., yT )
assumed to be generated by a m-state HMM with parameters Ψ = (θ,Γ), can be
expressed as the sum for all possible hidden state sequences sT :
f(yT |Ψ) =
∑
sT
f(yT |sT , θ)f(sT |Γ)
where
f(yT |sT , θ) =
T∏
t=1
f(yt|st, θst)
and
f(sT |Γ) = P (S1 = i)
T∏
t=2
γst−1,st.
This family of models have been useful in many problems some examples are:
the analysis of DNA sequences [87], machine speech recognition [88], longitudinal
studies on epileptic seizures [89], misclassification of diseases outcomes [90], hospital
infections [91] and, of course, disease surveillance [23, 24, 25, 92].
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4.2.2 Application to influenza surveillance
The HMM were first applied to ILI surveillance data in 1999 by Le Strat and Carrat
[23]. In their work they proposed a two states homogenous HMM, epidemic and
non-epidemic, where in each of these states the weekly ILI rate was described by
a normally distributed cyclical model of period 52 plus a linear trend. Following
this first work others have emerged using the same line of approach, from which we
point out the work of Rath et al 2003 [24], that proposed independent and identical
distributed (i.i.d) exponential distributions for rates in the non-epidemic state and
i.i.d normal distributions for the rates in the epidemic state, and the work of Martinez-
Beneito et al 2008 [25], that modeled the one week lag differences of the weekly ILI
rates, considering that those for the non-epidemic state were normally distributed
with mean zero, and those for the epidemic state were described by an order one
autoregressive model.
As stated before the application of these models to ILI data had always the goal
to classify weeks as epidemic or non epidemic using all available data [23, 24] or,
like in Martinez-Beneito et al 2008 [25], to do this on an online basis, classifying the
last week available as epidemic or non-epidemic. This last paper has used a bayesian
approach for the hidden states and parameters estimation.
It is important to notice that these approaches did not have the objective of
predicting or forecasting the ILI rates or even to forecast the hidden Markov chain
state for the forthcoming weeks.
4.2.3 The non-homogenous HMM
Given our objective of nowcasting the current week ILI rate (not yet observed) and
the respective influenza activity state using the incomplete data collected by the ISS,
we need a model that enables the use of covariates with forecasting capacity. For
this purpose we propose the use of a HMM that allows the introduction of covari-
ates to model the weekly ILI rate and the sate transition probabilities. This late
innovation implies the use of a non homogenous HMM instead of a homogenous one
as in the previous literature [23, 24, 25], where the transition probabilities from the
non-epidemic to the epidemic state (the epidemic beginning) and from the epidemic
to the non-epidemic state (the end of the epidemic) were invariant in time.
Applications of non homogenous HMM have been described in a large variety of
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subjects, like modeling the duration of business cycles [93], precipitation occurrence
[94], the association between sulphur dioxide and meteorologic variables [95], esti-
mation of infection and recovery rates for highly polymorphic parasites [96]. More
specifically, we propose the application of a HMM where the state transition probabil-
ities are given by a time-dependent matrix Γt, with elements γtj,i = P (St = i|St−1 = j)
for any i, j ∈ {0, 1} and t = 2, ..., T , where 0 and 1 represent, respectively, the non-
epidemic and the epidemic state of influenza activity,
Γt =
[
γt0,0 γ
t
0,1
γt1,0 γ
t
1,1
]
.
Choosing the transition probabilities to be modeled by a logistic function of the
covariates [97, 95],
logit(γtj,i) = ln
(
γtj,i
γtj,j
)
= αj,iZ t
γtj,i =
exp(αj,iZ t)
(1 + exp(αj,iZ t))
for any i, j ∈ {0, 1} and j 6= i, where Z t = (1, z1,t, ..., zq,t) is a vector of q covariates
measured in time t. The non homogeneity of the state transition probabilities can
preclude the stationarity of the Markov chain [97]. This can happen mainly when the
covariates used are functions of time. In this situation, an initial distribution for the
non homogenous hidden Markov chain is defined by δ = (δ0, δ1), δi = P (S1 = i) with
i ∈ {0, 1}.
To better understand the advantages of the non homogenous HMM we apply this
model to the data collected by the Portuguese ISS. For comparison purposes we also
apply to the same data an equivalent model with a homogenous hidden Markov chain.
4.3 Data description
In Portugal the clinical component of the ISS is assured by a network of 144 volun-
tary GP’s (“Medicos Sentinela”) that, since 1989, weekly report the ILI cases3 that
occurred among their patient list [83, 98] to the surveillance system hub (since year
2000, the Department of Epidemiology of Instituto Nacional de Sau´de Dr. Ricardo
Jorge), by regular mail or using a web-based questionnaire. The population under
3ILI definition used by the ICPC - WONCA
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observation, comprising the total of the GP patients lists, represents a sample fraction
of 2.5% of the total population.
The laboratorial component is coordinated by the National Influenza Reference
Laboratory and consists in receiving swabs from ILI cases sent by a fraction of GPs
from the sentinel system and from the network of emergency departments from hos-
pitals and health centers for virological surveillance purposes.
The Portuguese system, as part of the EISN, calculates and reports each Wednes-
day to TESSy system, the age-specific ILI incidence rates and the number of ILI cases
with laboratory confirmed influenza infection corresponding to the week before4. This
is done because there are delays in the system, namely the time between the patient
onset of symptoms to the GP visit and the GP reporting time to the surveillance
system.
In order to have a predictor of the ILI rate reported to ECDC by Wednesday,
the Portuguese ISS has been calculating the age-specific ILI incidence rates for each
week with the incomplete data gathered on Friday of that same week, from season
2008-2009 to 2010-2011. Our main goal is to access if there is enough information in
this variable to be used as predictor for an early detection of the epidemic start, peak
and end.
In synthesis, the data used in this study is the weekly ILI incidence rate (per
100,000 inhabitants) of week t calculated by Friday of week t, referred as yt(t), and
the weekly ILI rate calculated by Wednesday of week t+1, referred as yt(t+1) (Figure
4.2), for the period from week 40 of 2008 to week 16 of 2011. Virological data consists
of the weekly number of ILI cases with laboratory confirmation for the influenza virus
corresponding to week t, but calculated by Wednesday of week t+ 1: vt(t+1).
4.4 Models
The main objective is to nowcast the influenza activity state and the Wednesday ILI
rates for week t, calculated in week t + 1, using available data from covariates at
time t, namely the early estimate of the ILI rates by Friday and the number of ILI
cases tested positive for influenza for the previous week, estimated by Wednesday of
the present week, vt−1(t). To achieve this goal a HMM, based on the work developed
by Paroli and Spezia 2008 [95], that allows the inclusion of covariates in response
4The date of reference is the disease onset date
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Figure 4.2: Influenza-like illness incidence rates calculated by Friday of week t and
by Wednesday of week t+ 1.
variable and in the transition state probabilities is proposed.
From our observation, the influenza epidemic is sustained when the number of
ILI cases tested positive for influenza in a certain week is high, e.g 20. On the other
hand if the number ILI case confirmed for influenza is zero, the influenza activity
state is clearly non epidemic. Based on this, if an increase in the ILI rate is observed
without ILI cases confirmed for influenza, one can not assume that this increase is due
to an influenza epidemic, but can be related to the circulation of other respiratory
viruses. Using this empirical thresholds, two covariates that are functions of the early
estimate of the ILI rate and of the number of ILI cases positive for influenza in the
previous week are proposed. The objective of these two covariates is to enhance the
capacity of the models to discriminate an observed ILI rate as belonging to either
the epidemic or non epidemic period, keeping its prediction ability: one covariate to
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model the response variable in the non epidemic period,
yt(t)0 =
{
yt(t) vt−1(t) ≤ ν0
0 otherwise
, (4.1)
and the other to model the response variable in the epidemic period,
yt(t)1 =
{
yt(t) vt−1(t) ≥ ν1
0 otherwise
. (4.2)
In this study ν0 was set at 20 and ν1 to 1. As can be seen, both variables share
a common part of the early estimate of the ILI rate yt(t), i.e. the weeks where the
number of ILI cases tested positive, in the previous week, is higher or equal to 1 and
lower or equal to 20.
Baring this in mind, the weekly incidence rate calculated by Wednesday yt(t+1)
is assumed to be described by the following equations, conditional on the influenza
activity state:
yt(t+1) =
{
µ+ β1 cos(
2pit
52 ) + β2 sin(
2pit
52 ) + θ0,1yt(t)0 + et,0 St = 0
µ+ β1 cos(
2pit
52 ) + β2 sin(
2pit
52 ) + θ1,1yt(t)1 + θ1,2y
2
t(t)1 + et,1 St = 1
(4.3)
were et,i ∼ N(0, τi), with precision τ0 > τ1, t = 1, ..., T and i ∈ {0, 1}. Given that
the epidemic state is characterized by values of ILI rate higher than the ones in the
non epidemic state, a constraint that forces the variance of the epidemic state to be
higher than the variance of the non epidemic state is included in the model.
In this model we propose a common component for the epidemic and non-epidemic
period that reflects the baseline behavior of the ILI rates. This component is con-
stituted by a common mean µ and a cyclical component of period 52 weeks. The
difference between the equations for each state is set on the association with the
predictor, i.e. the state specific variables that are functions of the early estimate of
the ILI rate on Friday of week t, presented in equations 4.1 and 4.2. So, for the
non-epidemic model a linear association with yt(t)0 is considered and, on other hand,
the epidemic period is described by a quadratic association with yt(t)1. We propose
these two state dependent equations, from the observation of Figure 4.3 and with the
rational that, during the non epidemic period, i.e. for weeks with zero or a very small
number of ILI cases tested positive, the number of ILI cases are uniformly distributed
within the week, so the relation between the early estimate of ILI rate by Friday and
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the ILI rate estimated by Wednesday of the following week is linear. On the other
hand, during the epidemic period, the distribution of the ILI cases within each week
will not be uniform, presenting a sharp growth or decrease, respectively, in the begin-
ning and at the end of the epidemic. Given this, we propose for the epidemic period,
the quadratic form to model the association between the two ILI rates estimates.
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Figure 4.3: Association between ILI incidence rates calculated by Friday of week t
and by Wednesday of week t+1 according to the number of ILI cases tested positive
for influenza in the previous week vt−1(t). Black line represents yt(t+1) = yt(t)
For the hidden Markov chain state transition probabilities a time-varying matrix
with elements γtj,i for any i, j ∈ {0, 1} and t = 2, ..., T was considered. For a specific
week t, γt0,1 and γ
t
1,1 represent the probability that in week t the influenza activity is
epidemic given that in the week before the influenza activity was respectively in the
non-epidemic or in the epidemic state.
Given these considerations, three models are proposed (Models 0, 1 and 2). All
three share the same model for the response variable, expressed in equation 4.3, but
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have different choices for the state transition probabilities. Models 1 and 2 have a non-
homogenous hidden Markov chain, that are differentiated according to the covariates
used in the logistic function that models the transition probabilities:
• Model 1:
logit(γtj,i) = ln
(
γtj,i
γtj,j
)
= αj,i,0 + αj,i,1yt(t)
γtj,i =
exp(αj,i,0 + αj,i,1yt(t))
(1 + exp(αj,i,0 + αj,i,1yt(t)))
• Model 2:
logit(γtj,i) = ln
(
γtj,i
γtj,j
)
= αj,i,0 + αj,i,1yt(t) + αj,i,2vt−1(t)
γtj,i =
exp(αj,i,0 + αj,i,1yt(t) + αj,i,2vt−1(t))
(1 + exp(αj,i,0 + αj,i,1yt(t) + αj,i,2vt−1(t)))
for any j, i ∈ {0, 1} and j 6= i.
More specifically, for Model 1, the transition probabilities from the non-epidemic
state to the epidemic state and vice versa are modeled by the early estimate of the ILI
incidence rate. In Model 2 transition probabilities are modeled by the early estimate
of ILI incidence rate and by the absolute number of ILI cases tested positive for
influenza in the week before.
Finally for Model 0 a homogenous hidden Markov chain is used, where γti,j = γi,j
for any t = 2, ..., T and for any j, i ∈ {0, 1}, with the objective of evaluating the
additional value of a non homogenous hidden Markov chain.
4.5 Parameters and hidden states estimation
The model parameters Ψ = (µ,τ ,θ,β,α)and the hidden states sT for the non-
homogenous models 1 and 2, and Ψ = (µ,τ ,θ,β,γ) for the homogenous model 0
are numerically estimated using a bayesian approach via Markov chain Monte Carlo
(MCMC) methods. For the homogenous model 0, all the parameters are sampled
using the Gibbs algorithm, for the non-homogenous models 1 and 2 exception is
made for the parameters α of the transition probabilities that are sampled using
a Metropolis-Hastings algorithm. The state sequence sT is sampled using the ff-bs
algorithm: forward filtering - backward sampling algorithm [95, 99].
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4.5.1 Parameters prior distribution
The initial distribution of the hidden Markov chain is fixed as an uniform discrete
distribution (δ0 = δ1 =
1
2). The parameter independent prior distributions are set as:
• for all the models:
– µ ∼ N(µM , σ
2
M ) where µM = 50 and σ
2
M = 10 given that, empirically the
rate of 50 ILI cases per 100,000 was the value above which Public Health
officials in Portugal considered the start of the epidemic when baseline
approaches were absent;
– τi ∼ Gamma(ατ ;βτ ), where ατ = βτ = 0.5, under the increasing order
constraint (τ0 > τ1), for i = 0, 1;
– θ0 ∼ N(µθ;σ
2
θ) where µθ = 0 and σ
2
θ = 10;
– θ1 ∼ N2(µθ; Σθ) where µθ = (0, 0) and Σθ = 10I2;
– β = (β1, β2) ∼ N2(µB ; ΣB) where µB = (0, 0) and ΣB = 5I2; where In is
the identity matrix of dimension n.
• for Model 0: γ0 = (γ0,0, γ0,1) and γ1 = (γ1,0, γ1,1) ∼ Diriclet(λ1, λ2) where
λ1 = λ2 = 1;
• for Model 1: α0,1 = (α0,1,0, α0,1,1) and α1,0 = (α1,0,0, α1,0,1) ∼ N2(µA; ΣA),
where µA = (0, 0) and ΣA = 10I2;
• for Model 2: α0,1 = (α0,1,0, α0,1,1, α0,1,2) and α1,0 = (α1,0,0, α1,0,1, α1,0,2) ∼
N3(µA; ΣA), where µA = (0, 0, 0) and ΣA = 10I3.
4.5.2 Parameters posterior distribution
For the non homogenous models the posterior distribution of Ψ is then given by:
pi
(
Ψ, sT |yT(+1), y
T
0 ,C ,Z,δ
)
(4.4)
= pi
(
µ,τ , θ0, θ1,β ,α,s
T |yT(+1), y
T
(0)0, y
T
(0)1,C ,Z,δ
)
∝ f
(
yT(+1)|µ,τ , θ0, θ1,β ,α,s
T , yT(0)0, y
T
(0)1,C
)
f
(
sT |α,Z,δ
)
p(µ)p(τ )p(θ0)p(θ1)p(β)p(α)
where yT(+1) = (y1(2), ..., yT (T+1))
′ is the vector of the incidence rates estimated by
Wednesday of week t+ 1, sT = (s1, ..., sT ) is the states vector of the hidden Markov
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chain, yT(0)0 = (y1(1)0, ..., yT (T )0)
′ and yT(0)1 = (y1(1)1, ..., yT (T )1)
′ are the state specific
vectors of the early estimate of the incidence rate calculated by Friday of week t, C =
(c1, c2) is a 2×T matrix of the periodic component c1 = (cos(
2pi
52 ), ..., cos(
2tpi
52 ), ..., cos(
2Tpi
52 ))
′
and c2 = (sin(
2pi
52 ), ..., sin(
2tpi
52 ), ..., sin(
2Tpi
52 ))
′ and Z = (1, yT(0)) for Model 1 and Z =
(1, yT(0), v
T−1
(+1)) for Model 2 are respectively the vector and matrix of the covariates
included in state transition probabilities matrix, where vT−1(+1) = (v0(1), ..., vT−1(T ))
′.
The likelihood can be factorized as:
f
(
yT(+1)|µ,τ , θ0, θ1,β ,α,s
T , yT(0)0, y
T
(0)1,C
)
=
=
T∏
t=1
f(yt(t+1)|µ,τ , θ0, θ1,β , st, yt(t)0, yt(t)1, c1,t, c2,t)
Here f(yt(t+1)|µ,τ , θ0, θ1,β , st, yt(t)0, yt(t)1, c1,t, c2,t) is given by:
√
τ0
2pi
exp
{
−
τ0
2
(
yt(t+1) − µ− β1c1,t − β2c2,t − θ0yt(t)0
)2}
when st = 0 and
√
τ1
2pi
exp
{
−
τ1
2
(
yt(t+1) − µ− β1c1,t − β2c2,t − θ1,1yt(t)1 − θ1,2y
2
t(t)1
)2}
if st = 1.
The joint distribution of the hidden states is given by:
f(sT |α,Z,δ) = δs1
T∏
t=2
γtst−1,st
For the homogenous HMM (Model 0) the state transition probabilities γti,j = γi,j,
i.e. are obviously not indexed in time.
Finally, the posterior probability that a week t belongs to the epidemic state is
given by the posterior mean of each st, being estimated as:
Pˆ [St = 1] =
K∑
k=1
s
(k)
t
K
where s
(k)
t ∈ {0, 1} are the sampled states in each iteration and K is the total num-
ber of iterations of the MCMC algorithm, after burn-in period and thinning. The
classification of each week in the epidemic on non epidemic state is named as state
decoding.
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4.5.3 MCMC algorithm used for bayesian inference
The bayesian inference of the proposed HMM is done by sampling from the posterior
distribution (equation 4.5).
More specifically, given the parameters vector:
Ψ(k−1) =
(
µ(k−1), τ (k−1),β (k−1), θ
(k−1)
0 , θ
(k−1)
1 ,α
(k−1)
)
(for the homogenous model α(k−1) is substituted by γ (k−1)) and the hidden states
sT (k−1), generated in the k-1 iteration under the constraint τ
(k−1)
0 > τ
(k−1)
1 , the
generic steps to obtain their values in the k iteration are described bellow, followed
by the calculation of all the posterior distributions involved:
1. The state sequence sT (k) is generated by the ff-bs algorithm;
2. The precisions τi, i = 0, 1 are generated independently from their full condi-
tional distribution which are Gamma distributions. Here the increasing order
constrain must be applied if τ
(k)
0 ≤ τ
(k)
1 . In this situation a permutation must
applied to the state specific parameter values in order to change the values
attributed to the non-epidemic state to the epidemic state and vice versa;
3. The full conditional distribution from which the signal value µ(k) of the common
part is generated from is a Normal distribution;
4. The vector of parameters β (k)
(
β
(k)
1 , β
(k)
2
)
are generated from their full condi-
tional posterior distribution which is a Multivariate Normal distribution;
5. The parameters θ
(k)
0 and θ
(k)
1 are independently generated from their full con-
ditional posterior distributions, which are Normal and Multinormal;
6. For the homogenous model: the i -th row of Γk matrix is generated from
Dirichlet distribution. For the non-homogenous models the transition prob-
abilities matrix parameters α0,1 and α1,0 are sampled using a random-walk
Metropolis-Hastings algorithm.
The forward filtering-backward sampling algorithm
The ff-bs algorithm was developed in order to sample the sequence of hidden states
sT from the full conditional joint distribution of the states. This method was first
proposed by Chib S in 1996 [99]. Here the rational of the algorithm is described.
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Consider the full conditional joint distribution of the states:
P
(
sT |yT(+1),Ψ,D
)
= P (sT |y
T
(+1),Ψ,D)
T−1∏
t=1
P (st|y
T
(+1), s
T
t+1Ψ,D)
where D = (yT(0),C,Z ), s
T
t+1 = (st+1, ..., sT ).
Given this expression the objective of the ff-bs algorithm is to sample each of the
states st from P (st|y
T
(+1), s
T
t+1,Ψ,D) for t = 1, ..., T − 1 and from P (sT |y
T
(+1),Ψ,D)
for t = T .
Developing the generic term one gets,
P (st|y
T
(+1), s
T
t+1,Ψ,D) =
P (st, s
T
t+1, y
t
(+1), y
T
t+1(+1),Ψ,D)
P (sTt+1, y
T
(+1),Ψ,D)
∝ f(yTt+1(+1), s
T
t+1|st, y
t
(+1),Ψ,D)P (st, y
t
(+1),Ψ,D)
= f(yTt+1(+1), s
T
t+1|st, y
t
(+1),Ψ,D)P (st|y
t
(+1),Ψ,D)f(y
t
(+1),Ψ,D)
∝ f(yTt+1(+1), s
T
t+1|st, y
t
(+1),Ψ,D)P (st|y
t
(+1),Ψ,D)
= f(yTt+1(+1), s
T
t+2|st+1, y
t
(+1),Ψ,D)P (st+1|st, y
t
(+1),Ψ,D)P (st|y
t
(+1),Ψ,D)
∝ P (st+1|st,Ψ,D)P (st|y
t
(+1),Ψ,D),
given that f(yTt+1(+1), s
T
t+2|st, st+1, y
t
(+1),Ψ,D) does not depend on st.
So the generic term of the full conditional joint distribution of states can be
derived from the product between P (st+1|st,Ψ,D), the state transition probability,
and P (st|y
t
(+1),Ψ,D).
In order to have a mass function this expression must be divided by a normalizing
constant, so that:
P (st = i|y
T
(+1), st+1 = j,Ψ,D) =
P (st = i|y
t
(+1),Ψ,D)P (st+1 = j|st = i,Ψ,D)∑1
k=0 P (st = k|y
t
(+1),Ψ,D)P (st+1 = j|st = k,Ψ,D)
Where i, j ∈ {0, 1} and j is the state observed in the moment t+ 1.
From here it can be easily seen that sampling each state depends on the calculation
of P (st|y
t
(+1),Ψ,D).
In order to calculate this probability Chib S [99] proposed in 1996 a method based
on a update step followed by a prediction one.
This method is supported by the following result,
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P (st|y
t
(+1),Ψ,D) = P (st|yt(t+1), y
t−1
(+1),Ψ,D) =
P (st, yt(t+1)|y
t−1
(+1),Ψ,D)
f(yt(t+1)|y
t−1
(+1),Ψ,D)
,
∝ P (st, yt(t+1)|y
t−1
(+1),Ψ,D) = f(yt(t+1)|y
t−1
(+1), st,Ψ,D)P (st|y
t−1
(+1),Ψ,D),
with mass function,
P (st = i|y
t
(+1),Ψ,D) =
f(yt(t+1)|y
t−1
(+1), st = i,Ψ,D)P (st = i|y
t−1
(+1),Ψ,D)∑1
k=0 f(yt(+1)|y
t−1
(+1), st = k,Ψ,D)P (st = k|y
t−1
(+1),Ψ,D)
.
On the other hand from the law of total probability, one can assume that,
P (st|y
t−1
(+1),Ψ,D) =
1∑
k=0
P (st|st−1 = k,Ψ,D)P (st−1 = k|y
t−1
(+1),Ψ,D).
So, if the procedure is initialized considering that P (s1|Ψ,D) is given by δ , the
probability distribution of the initial state, then, the probabilities P (st|y
t
(+1),Ψ,D)
can be obtained from t = 2, ..., T , assuming that P (st−1|y
t−1
(+1),Ψ,D) is available, as
follows,
Prediction step:
P (st = i|y
t−1
(+1),Ψ,D) =
1∑
k=0
P (st = i|st−1 = k,Ψ,D)P (st−1 = k|y
t−1
(+1),Ψ,D)
for i ∈ {0, 1},
Update step:
P (st = i|y
t
(+1),Ψ,D) =
f(yt(t+1)|y
t−1,Ψ,D, st = i)P (st = i|y
t−1
(+1),Ψ,D)∑1
k=0 f(yt(t+1)|y
t−1
(+1), st = k,Ψ,D)P (st = k|y
t−1
(+1),Ψ,D)
for i ∈ {0, 1}.
At t = T the forward filtering phase of the algorithm ends and the backward sam-
pling phase is initiated by sampling sT from a Bernoulli distribution with probabilities
P (sT = i|y
T
(+1),Ψ,D) for i ∈ {0, 1}.
This backward sampling phase corresponds to the procedure of sampling the hid-
den states vector sT from their full conditional joint distribution. So, each of the
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remaining T − 1 states, is sampled going backwards (for t = T − 1, ..., 1), from a
Bernoulli distribution with probabilities:
P (st = i|y
T
(+1), st+1 = j,Ψ,D) =
P (st = i|y
t
(+1),Ψ,D)P (st+1 = j|st = i,Ψ,D)∑1
k=0 P (st = k|y
t
(+1),Ψ,D)P (st+1 = j|st = k,Ψ,D)
for i ∈ {0, 1}.
Posterior distribution of τ = (τ0, τ1)
The full conditional posteriori distribution of τ is given by:
f(τ |yT(+1), s
T ,Ψ,D) =
= f(τ0|y
T
(+1), s
T = 1,Ψ,D)f(τ1|y
T
(+1), s
T = 0,Ψ,D)
where sT = i for i ∈ {0, 1}, represents that each distributions is conditioned on the
subsets of yT(+1) and D where {t ≥ 1 : st = i}.
Lets now consider that,
f(τi|y
T
(+1), s
T = i,Ψ,D) ∝ f(yT(+1)|s
T = i,Ψ,D)p(τi)
were p(τi) is the priori distribution of the parameters, τi defined as Gamma(ατ , βτ ).
So for i = 0, considering that yt(t+1)|st = 0,Ψ,D ∼ N(µ + β1c1,t + β2c2,t +
θ0yt(t)0, τ0) for {t ≥ 1 : st = 0} the posterior distribution of τ0 will be Gamma with
parameters,
α0 = ατ +
T0
2
β0 = βτ +
1
2
∑
{t≥1:st=0}
(
yt(t+1) − µ− β1c1,t − β2c2,t − θ0yt(t)0
)2
,
where T0 is the number of observations that corresponds to the state 0.
This results comes from the fact that the Gamma distribution is a conjugate prior
for the Normal likelihood and Ψ is known.
Identically applying the same rule for i = 1, shows that the posterior distribution
of τ1 is Gamma distributed with parameters:
α1 = ατ +
T1
2
.
β1 = βτ +
1
2
∑
{t≥1:st=1}
(
yt(t+1) − µ− β1c1,t − β2c2,t − θ1,1yt(t)1 − θ1,1y
2
t(t)1
)2
,
where T1 is the number observations that corresponds to the state 1.
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Posterior distribution of µ
The full conditional posteriori distribution of µ is given by:
f(µ|yT(+1), s
T ,Ψ,D)
∝ f(yT(+1)|s
T ,Ψ,D)p(µ)
were p(µ) is the priori distribution of µ defined as Normal with mean µM and variance
σ2M .
Developing this expression:
f(yT(+1)|s
T ,Ψ,D)p(µ) =
=
∏
{t≥1:st=0}
f(yt(t+1)|st = 0,Ψ,D)
∏
{t≥1:st=1}
f(yt(t+1)|st = 1,Ψ,D)p(µ) ∝
∝
∏
{t≥1:st=0}
exp{− τ02 (yt(t+1) − µ− β1c1,t − β2c2,t − θ0yt(t)0)
2}∏
{t≥1:st=1}
exp{− τ02 (yt(t+1) − µ− β1c1,t − β2c2,t − θ1,1yt(t)1 − θ1,2y
2
t(t)1)
2}
exp{− τM2 (µ − µM)
2} ∝
∝
∏
{t≥1:st=0}
exp{− τ02 (µ
2 − 2µy˜0t(t+1))}
∏
{t≥1:st=1}
exp{− τ12 (µ
2 − 2µy˜1t(t+1))}
exp{− τM2 (µ
2 − 2µµM )} = (∗)
where
y˜0t(t+1) = yt(t+1) − β1c1,t − β2c2,t − θ0yt(t)0
for {t ≥ 1 : st = 0} and
y˜1t(t+1) = yt(t+1) − β1c1,t − β2c2,t − θ1,1yt(t)1 − θ1,2y
2
t(t)1
for {t ≥ 1 : st = 1}.
Continuing the development:
(∗) = exp{− τ02 (T0µ
2 − 2µ
∑
{t≥1:st=0}
y˜0t(t+1)) −
τ1
2 (T1µ
2 − 2µ
∑
{t≥1:st=1}
y˜1t(t+1))}
exp{− τM2 (µ
2 − 2µµM )} =
where T0 and T1 is the number of observations that corresponds respectively to the
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state 0 (non epidemic) and 1 (epidemic).
= exp{−µ
2
2 (τ0T0 + τ1T1) + µτ0
∑
{t≥1:st=0}
y˜0t(t+1) + µτ1
∑
{t≥1:st=1}
y˜1t(t+1)}
exp{− τM2 (µ
2 − 2µµM )} =
exp{−µ
2
2 (τ0T0 + τ1T1 + τM ) + µ(τ0
∑
{t≥1:st=0}
y˜0t(t+1) + τ1
∑
{t≥1:st=1}
y˜1t(t+1)) + µMτM} =
= exp{− τ0T0+τ1T1+τM2
[
µ2 − 2µ
(
τ0
∑
{t≥1:st=0}
y˜0
t(t+1)
+τ1
∑
{t≥1:st=1}
y˜1
t(t+1)
+µM τM
τ0T0+τ1T1+τM
)]
} ∝
∝ exp{− τ0T0+τ1T1+τM2
(
µ−
τ0
∑
{t≥1:st=0}
y˜0
t(t+1)
+τ1
∑
{t≥1:st=1}
y˜1
t(t+1)
+µM τM
τ0T0+τ1T1+τM
)2
}
From which we can conclude that the full conditional posterior distribution of µ
is Normal distributed with mean:
τ0
∑
{t≥1:st=0}
y˜0t(t+1) + τ1
∑
{t≥1:st=1}
y˜1t(t+1) + µMτM
τ0T0 + τ1T1 + τM
and precision τ0T0 + τ1T1 + τM .
Posterior distribution of β = (β1, β2)
The full conditional posteriori distribution of β is given by:
f(β |yT(+1), s
T ,Ψ,D)
∝ f(yT(+1)|s
T ,Ψ,D)p(β)
where p(β) is the priori distribution of β defined as Multivariate Normal with mean
µB and covariance matrix ΣB. Note that,
f(yT(+1)|s
T ,Ψ,D)p(β) ∝
∝
∏
{t≥1:st=0}
exp{− τ02 (yt(t+1) − µ− θ0yt(t)0 − β1c1,t − β2c2,t)
2}∏
{t≥1:st=1}
exp{− τ12 (yt(t+1) − µ− θ1,1yt(t)1 − θ1,2y
2
t(t)1 − β1c1,t − β2c2,t)
2}
exp
{
−12(β − µB)
′Σ−1B (β − µB)
}
can be rewriten in the following matrix form:
= exp
{
−
1
2
(y˜T(+1) −Cβ)
′Q(y˜T(+1) −Cβ)
}
exp
{
−
1
2
(β − µB)
′Σ−1B (β − µB)
}
∝
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where Q is the diagonal matrix whose the tth term is τ0 if st = 0 or τ1 if st = 1. On
the other hand y˜T(+1) is the vector with generic terms
(
yt(t+1) − µ− θ0yt(t)0
)
if st = 0
or
(
yt(t+1) − µ− θ1,1yt(t)1 − θ1,2y
2
t(t)1
)
if st = 1.
Continuing the development produces,
∝ exp
{
−12(y˜
T ′
(+1)Qy˜
T
(+1) − 2β
′C ′Qy˜T(+1) + β
′C ′QCβ)− 12(β
′Σ−1B β − 2β
′Σ−1B µB + µ
′
BΣ
−1
B µB)
}
∝
∝ exp
{
−12
[
β ′
(
C ′QC +Σ−1B
)
β − 2β ′
(
C ′Qy˜T(+1) +Σ
−1
B µB
)]}
So considering that Λβ = C
′QC + Σ−1B and µβ = Λ
−1
β (C
′Qy˜T(+1) + Σ
−1
B µB) the full
conditional posterior distribution of β will be proportional to:
∝ exp
{
β − µβ)
′Λβ(β − µβ)
}
This means that the full conditional posterior distribution of β is Multivariate Normal
distributed with mean:
µβ = (Σ
−1
B +C
′QC)−1(Σ−1B µB +C
′Qy˜T(+1))
and matrix precision:
Λβ = (Σ
−1
B +C
′QC )
Posterior distribution of θ0 and θ1 = (θ1,1, θ1,2)
The full conditional posteriori distribution of θ0 is given by:
f(θ0|y
T
(+1), s
T = 0,Ψ,D)
∝ f(yT(+1)|s
T = 1,Ψ,D)p(θ0),
were p(θ0) is the prior distribution of θ0, defined as Normal with mean µθ and precision
τθ = σ
−2
θ ,
∝
∏
{t≥1:st=0}
exp
{
− τ02 (yt(t+1) − µ− β1c1,t − β2c2,t − θ0yt(t)0)
2
}
exp
{
− τθ2 (θ0 − µθ)
2
}
∝ exp
{
− τ02
∑
{t≥1:st=1}
(θ0yt(t)0)
2 − 2(θ0yt(t)0(yt(t+1) − µ− β1c1,t − β2c2,t))
}
exp
{
− τθ2 (θ
2
0 − 2µθθ0)
}
= exp
{
−
τ0
∑
{t≥1:st=0}
y2
t(t)0
−τθ
2
[
θ20 −
2θ0
(
τ0
∑
{t≥1:st=0}
yt(t)0(yt(t+1)−µ−β1c1,t−β2c2,t)+µθτθ
)
τ0
∑
{t≥1:st=0}
y2
t(t)0
−τθ
]}
∝ exp
{
−
τ0
∑
{t≥1:st=0}
y2
t(t)0
−τθ
2
(
θ0 −
τ0
∑
{t≥1:st=0}
yt(t)0(yt(t+1)−µ−β1c1,t−β2c2,t)+µθτθ
τ0
∑
{t≥1:st=0}
y2
t(t)0
−τθ
)2}
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Concluding that the full conditional posterior distribution of θ0 is Normal dis-
tributed with mean,
τ0
∑
τ0{t≥1:st=0}
yt(t)0(yt(t+1) − µ− β1c1,t − β2c2,t) + µθτθ
τ0
∑
{t≥1:st=0}
y2t(t)0 − τθ
,
and precision,
τ0
∑
{t≥1:st=0}
y2t(t)0 − τθ.
The full conditional posteriori distribution of θ1 = (θ1,1, θ1,2) is given by:
f(θ1 |y
T
(+1), s
T = 1,Ψ,D)
∝ f(yT(+1)|s
T = 1,Ψ,D)p(θ1)
were p(θ1) is the prior distribution of θ1, defined as Multivariate Normal with mean
µθ and covariance matrix Σθ. Notice that,
f(yT(+1)|s
T = 1,Ψ,D)p(θ1) ∝
∝
∏
{t≥1:st=1}
exp{− τ12 (yt(t+1) − µ− β1c1,t − β2c2,t − θ1,1yt(t)1 − θ1,2y
2
t(t)1)
2}
exp
{
−12(θ1 −µθ)
′Σ−1θ (θ1 −µθ)
}
can be rewriten in the following matrix form,
exp
{
−
1
2
(y˜T(+1) − Y˜ (0)θ1)
′Q1(y˜
T
(+1) − Y˜ (0)θ1)
}
exp
{
−
1
2
(θ1 −µθ)
′Σ−1θ (θ1 −µθ)
}
where Q1 is the diagonal matrix which the tth term is τ1 if st = 1 and zero otherwise.
On the other hand, y˜T(+1) is the vector with generic terms
(
yt(t+1) − µ− β1c1,t − β2c2,t
)
if st = 1 and zero otherwise, and Y˜ (0) = (y
T
(0), (y
T
(0))
2).
Following the same calculations applied to obtain the full conditional posterior
distribution of β , one can conclude that the full conditional posterior distribution of
θ1 is Multivariate Normal distributed with mean,
(Σ−1θ + Y˜
′
(0)Q1Y˜ (0))
−1(Σ−1θ µθ + Y˜
′
(0)Q1 y˜
T
(+1))
and matrix precision:
(Σ−1θ + Y˜
′
(0)Q1Y˜ (0)).
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Posterior distribution of the parameters associated with the state transi-
tion probabilities matrix
Consider first the homogenous case. The full conditional posteriori distribution of
Γ is given by:
f(Γ|sT , δ) =
= f(γ0|s
T = 0, δ)f(γ1|s
T = 1, δ)
where γ0 and γ1 are respectively the first and second row of the state transition
probabilities matrix. So the posterior distribution of γ0 is given by:
f(γ0|s
T = 0, δ) ∝ pi(sT = 0|γ0, δ)p(γ 0)
where p(γ0), the prior distribution of γ0 , is defined as Dirichlet(λ1, λ2). Then,
∝ δs1
∏
{t≥2:st−1=0}
γst−1,st
1
B(λ1, λ2)
γλ1−10,0 γ
λ2−1
0,1
where B(λ1, λ2) is the beta function and
= δs1
1
B(λ1, λ2)
γ
n0,0
0,0 γ
n0,1
0,1 γ
λ1−1
0,0 γ
λ2−1
0,1
where n0,0 and n0,1 are respectively the number of pairs of observations with states
non epidemic followed by non epidemic, and states non epidemic followed by the
epidemic. So,
f(γ0|s
T = 0, δ) ∝
1
B(n0,0 + λ1, n0,1 + λ2)
γ
n0,0+λ1−1
0,0 γ
n0,1+λ1−1
0,1
Showing that the full conditional posterior distribution of γ0 is Dirichlet(n0,0 +
λ1, n0,1 + λ2). For parameter γ1, the second row of the state transition probabilities
matrix, we conclude analogously that the full conditional posterior distribution is
Dirichlet(n1,0+λ1, n1,1+λ2) where n1,0 and n1,1 are respectively the number of pairs
of observations with states epidemic followed by non epidemic and states epidemic
followed by epidemic.
Lets now focus on the non-homogenous case. For model 1 and 2 the parameters
α0,1 and α1,0 are sampled using a random walk Metropolis-Hastings algorithm. So
considering that α
(k−1)
i,j are the values of the parameters sampled in the k−1 iteration
of the algorithm, the parameters of the k iteration are independently sampled from
a random walk:
α
(k)
i,j = α
(k−1)
i,j + UA
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with i, j = 0, 1 and i 6= j, and UA is generated a from Multivariate Normal distribution
with parameters µA and covariance matrix ΣA. So, in each iteration the vectors α
(k)
0,1
and α
(k)
1,0 are accepted respectively with probability:
A(α
(k)
0,1 ,α
(k−1)
0,1 ) = min

1; pi
(
α
(k)
0,1|s
T (k),Z ,δ
)
pi
(
α
(k−1)
0,1 |s
T (k),Z ,δ
)


and
A(α
(k)
1,0,α
(k−1)
1,0 ) = min

1; pi
(
α
(k)
1,0|s
T (k),Z,δ
)
pi
(
α
(k−1)
1,0 |s
T (k),Z ,δ
)

 .
Here
pi
(
α
(k)
0,1 |s
T (k),Z ,δ
)
∝
∝ δ
s
(k)
1
∏
{t≥2:s
(k)
t−1=0}
γ
t(k)
s
(k)
t−1,s
(k)
t
exp{−1/2(α
(k)
0,1 − µA)
′Σ−1A (α
(k)
0,1 − µA)}
and
pi
(
α
(k)
1,0 |s
T (k),Z ,δ
)
∝
∝ δ
s
(k)
1
∏
{t≥2:s
(k)
t−1=1}
γ
t(k)
s
(k)
t−1,s
(k)
t
exp{−1/2(α
(k)
1,0 − µA)
′Σ−1A (α
(k)
1,0 − µA)}
where
γ
t(k)
j,i =
exp(α
(k)
j,i Z t)
(1 + exp(α
(k)
j,i Z t))
and Z t = (1, yt(t)) for model 1 and Z t = (1, yt(t), vt−1(t)) for model 2.
4.5.4 Nowcasting weekly influenza activity states and ILI rates
In order to simulate the online performance of the models, the influenza activity state
and the correspondent ILI rate of each week, from week 40/2010 to week 16/2011, were
nowcasted. Each proposed model was sequentially fitted to all the data known until
the respective previous week to nowcast the following. For example, week 40/2010
was nowcasted from week 40/2008 to week 39/2010, week 41/2010 was nowcasted
from week 40/2008 to week 40/2010, and so on.
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More specifically, consider that we are on Friday of week T , knowing all ILI rates
and ILI cases tested positive for influenza until week T − 1, and we want to nowcast
week T , using previous information and the incomplete estimate of the ILI rate of
week T . The probability that week T belongs to the epidemic influenza activity state
is estimated by:
Pˆ [ST = 1] =
K∑
k=1
Pˆ [ST = 1|Ψ
(k)]
K
(4.5)
where Pˆ [ST = 1|Ψ
(k)] = Pˆ [ST−1 = 1|Ψ
(k)]γ
T (k)
1,1 + Pˆ [ST−1 = 0|Ψ
(k)]γ
T (k)
0,1 , k is the
iteration step of the MCMC algorithm, Pˆ [ST−1 = 1|Ψ
(k)] is the probability that week
T−1 belongs to the epidemic state sampled in the kth iteration by the ff-bs algorithm
and γ
T (k)
j,i with j, i ∈ {0, 1} represent the transition probabilities sampled in the kth
iteration of the MCMC algorithm. For model 0 the transition probabilities sampled
in each iteration are not time-dependent γ
(k)
j,i , but for the non homogenous models
the transition probabilities are estimated using the known covariates at moment T
and the parameters α
(k)
j,i sampled in iteration k,
γ
T (k)
j,i =
exp(α
(k)
j,i ZT )
(1 + exp(α
(k)
j,i ZT ))
where ZT = (1, yT (T )) for model 1 and ZT = (1, yT (T ), vT−1(T )) for model 2.
The nowcasting of the ILI rate for week T to be reported on week T+1 is estimated
by:
yˆT (T+1) =
K∑
k=1
y
(k)
T (T+1)|s
(k)
T
=1
Pˆ [ST = 1|Ψ
(k)] + y
(k)
T (T+1)|s
(k)
T
=0
(1− Pˆ [ST = 1|Ψ
(k)])
K
(4.6)
where y
(k)
T (T+1)|s
(k)
T
=1
is sampled from f(yT (T+1)|µ
(k),β (k), τ
(k)
0 , θ
(k)
0 , yT (T )0, c1,T , c2,T )
and y
(k)
T (T+1)|s
(k)
T
=0
is sampled from f(yT (T+1)|µ
(k),β (k), τ
(k)
1 , θ
(k)
1 , yT (T )1, c1,T , c2,T ).
4.5.5 Model comparison and Marginal likelihood estimation
The Bayes factor was used in order to compare the models fit to data. For this
purpose marginal likelihoods were computed numerically using the method presented
by Chib 1995 [104], for the homogenous model, given that all parameters are sampled
using the Gibbs algorithm, and the method presented by Chib and Jeliazkov 2001
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[105] for the non homogenous models, since the transition probabilities parameters
are sampled via the Metropolis-Hastings algorithm.
In both approaches the natural logarithm of the marginal likelihood is numericaly
estimated via a MCMC algorithm in a special point Ψ∗ of the parameters space, the
posterior mode of Ψ.
Lets consider the estimate of the marginal likelihood:
fˆ(yT(+1)|D,δ) =
f(yT(+1)|Ψ
∗,D,δ)p(Ψ∗)
pˆi(Ψ∗|yT(+1),D,δ)
,
and its natural logarithm
ln(ˆf(yT(+1)|D,δ) = ln(2) + ln f(y
T
(+1)|Ψ
∗,D,δ) + ln p(Ψ∗)− ln pˆi(Ψ∗|yT(+1),D,δ) (4.7)
where the component ln(2) is added by suggestion of Neil 1999 [106], and represents
the constraint imposed to achieve the identifiability of the states(in our case τ0 > τ1).
This component is ln(m!) in the general case of an m-states model.
In order to estimate this logarithm, the MCMC algorithm presented in sec-
tion 4.5.3 is executed for K iterations and parameters runs used to calculate Ψ∗ =
(α∗0,1,α
∗
1,0, µ
∗, τ ∗, θ∗0, θ
∗
1,β
∗). In the next steps the second and third therm of equation
4.7 are calculated.
The seconde term of 4.7 is estimated estimated by,
ln f(yT(+1)|Ψ
∗,D,δ) =
T∑
t=1
ln
[
1∑
i=0
f(yT(+1)|Ψ
∗,D,δ, st = i)P (st = i|y
t
(+1),Ψ
∗,D)
]
where P (st = i|y
t
(+1),Ψ
∗,D) is the filtered probability obtained in the ff-bs algorithm.
The third term of 4.7 is estimated in the non homogenous model by:
ln p(Ψ∗) = ln p(µ∗)+ln p(β∗)+ln p(τ∗0 )+ln p(τ
∗
1 )+ln p(θ
∗
0)+ln p(θ
∗
1)+ln p(α
∗
0,1)+ln p(α
∗
1,0).
For the homogenous model the last two terms are replaced by ln p(γ0) and ln p(γ1)).
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The fourth term of 4.7 is calculated as follows:
ln pˆi(Ψ∗|yT(+1),D) (4.8)
= ln
[
K−1
K∑
k=1
(
A(α
(k)
0,1,α
∗
0,1)q(α
∗
0,1,α
(k)
0,1)A(α
(k)
1,0,α
∗
1,0)q(α
∗
1,0,α
(k)
1,0)
)]
− ln
[
K−1
K∑
k=1
A(α∗0,1, α
(k)
0,1)A(α
∗
1,0, α
(k)
1,0)
]
+ ln
[
K−1
K∑
k=1
pi(µ∗|yT(+1),D,α
∗, τ (k), θ(k),β (k), sT (k))
]
+ ln
[
K−1
K∑
k=1
1∏
i=0
pi(τ∗i |y
T
(+1),D,α
∗, µ∗, θ(k),β (k), sT (k))
]
+ ln
[
K−1
K∑
k=1
1∏
i=0
pi(θ∗i |y
T
(+1),D,α
∗, µ∗, τ ∗,β)(k), sT (k)
]
+ ln
[
K−1
K∑
k=1
pi(β∗|yT(+1),D,α
∗, µ∗, τ ∗, sT (k))
]
.
This terms are obtained by running for K extra iterations of MCMC algorithm
for each vector of parameters α, µ, τ , θ and β , i.e running a total of 5K times the
MCMC algorithm.
In the expression above all values labeled with superscript (k) are drawn from the
full conditional posterior distributions of each parameter µ, τ , θ and β . On the other
hand α
(k)
i,j with i 6= j are drawn from the random walk in the following way:
α
(k)
i,j = α
∗
i,j + UA
where UA is Multivariate Normal distributed with mean µA and covariance matrix
ΣA. Additionally q(α
∗
i,j,α
(k)
i,j ) represents the multivariate Normal probability density
function with mean α
(k)
i,j and covariance matrix ΣA measured in point α
∗
i,j, and
A(α
(k)
i,j ,α
∗
i,j) = min

1; pi
(
α
(k)
i,j |s
T (k),Z ,δ
)
pi
(
α∗i,j|s
T (k),Z ,δ
)


with i 6= j is the acceptance ratio of α
(k)
i,j in comparison with α
∗
i,j and A(α
∗
i,j,α
(k)
i,j ) its
reciprocal.
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For the homogenous case the first two terms of equation 4.9 are replaced by
ln
[
K−1
K∑
k=1
1∏
i=0
pi(γ∗i |y
T
(+1),D, µ
(k), τ (k), θ(k),β (k), sT (k))
]
and all the posterior distributions conditioned on α∗ are conditioned on γ∗i with
i ∈ {0, 1}.
4.6 Results
4.6.1 Application to all data set
In a first phase all models were applied to the entire time series, from week 40/2008
to week 16/2011. This procedure had the objective of comparing models regarding
the parameters estimates and the retrospective classification of each week in one
of the Markov chain states (epidemic or non-epidemic), i.e. the decoding of the
influenza activity states. Parameters and hidden states were estimated by a MCMC
run of 200,000 iterations with a burn-in of 60,000 and a thinning of 100, for the non
homogenous models, and 100,000 iterations with a burn-in of 25,000 and a thinning
of 50, for the homogenous one. All results presented in this Chapter were obtained
using specific programs implemented in the R computing language [100].
The MCMC output convergence was evaluated by the observation of the trace
and auto-correlation functions of the parameters runs (Appendix C), and by the
application of the statistic of Gelman-Rubin 1992 [101] and by the Raftery and Lewis
method 1992 [102]. For this purpose the R package coda was used [103]. For all
the parameters, the Gelman-Rubin scaling factors 97.5% percentiles were bellow 1.1,
on the other hand the Raftery and Lewis method applied to the 1,500 runs after
the burn-in and thin suggested for all the parameters a burn-in not superior to 2
and a maximum number of iterations close to 1,500. These results indicate that
convergency has been achieved enabling the computations of the posterior means and
credible intervals.
In Table 4.1 it can be seen that the non homogenous models present a better fit
to data and, among these, model 2 does better.
According to Table 4.2 the estimates of parameters of the response variable are
very similar between the three models. The only parameters that seem to change
(decreasing in value) with the increase of model complexity, i.e. the introduction of
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Model ln(mL)
M0 -332.384
M1 -320.111
M2 -300.397
Table 4.1: Natural logarithm of the marginal likelihoods of the proposed models.
covariates to model the state transition probability matrix, are the parameters of the
common part that has the objective of explaining ILI rate baseline behavior (µ, β1
and β2).
Model 0 Model 1 Model 2
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
τ0 0.134 [0.091;0.187] 0.137 [0.093;0.189] 0.139 [0.091;0.196]
τ1 0.006 [0.004;0.009] 0.006 [0.004;0.009] 0.006 [0.004;0.009]
µ 3.131 [2.191;4.120] 3.011 [1.995;3.993] 2.876 [1.845;3.950]
β1 -0.861 [-1.660;-0.048] -0.799 [-1.633;0.004] -0.720 [-1.517;0.133]
β2 1.947 [0.753;3.216] 1.861 [0.617;3.122] 1.604 [0.289;2.954]
θ0 0.710 [0.526;0.879] 0.726 [0.554;0.888] 0.739 [0.571;0.902]
θ1,0 1.556 [1.353;1.759] 1.571 [1.375;1.777] 1.576 [1.375;1.779]
θ1,1 -0.005 [-0.007;-0.003] -0.005 [-0.007;-0.003] -0.005 [-0.007;-0.003]
γ0,0 0.948 [0.888;0.986] NA NA NA NA
γ0,1 0.052 [0.014;0.112] NA NA NA NA
γ1,0 0.092 [0.025; 0.191] NA NA NA NA
γ1,1 0.908 [0.809;0.975] NA NA NA NA
α0,1,0 NA NA -3.282 [-4.823;-1.953] -3.267 [-5.077;-1.814]
α0,1,1 NA NA 2.015 [-1.874;5.589] 1.995 [-1.917;5.917]
α0,1,2 NA NA NA NA 0.778 [-4.822;5.626]
α1,0,0 NA NA -0.266 [-2.303;1.677] 0.326 [-1.943;2.786]
α1,0,1 NA NA -4.133 [-9.379;-0.826] -1.320 [-7.438;3.698]
α1,0,2 NA NA NA NA -9.866 [-25.726;-0.192]
Table 4.2: Posteriori means and 95% credible intervals for model parameters. NA:
not applicable.
Likewise the results obtained by Martinez-Beneito 2008 [25], for the homogenous
model, a week is more likely to belong to the epidemic state if the previous week
was in the epidemic state (γ1,1 posterior mean of 0.91). This conservative result is
also observed in the non-epidemic period, so a week is more likely to be in the non-
epidemic state if the previous week was in the non-epidemic state (γ0,0 posterior mean
of 0.95). This result also means that in each week the mean posterior probabilities of
entering in the epidemic state and also leaving the epidemic state are constant over
time and very low (respectively 0.05 for γ0,1 and 0.09 for γ1,0).
For the non homogenous models (Figure 4.4), and as it was expected, the pos-
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terior probabilities of changing the influenza activity state in each week vary over
time. Nevertheless some of the posterior 95% credible intervals for the transition
probabilities matrix parameters include zero (see Table 4.2). Exception are observed
for the probability of entering the epidemic state, in the constant (α0,1,0), that is
significant in both models, and for the probability of leaving the epidemic state, in
the parameters associated with the early estimate of ILI rate (α1,0,1), in model 1,
and the one associated with number of ILI cases positive for influenza in the previous
week(α1,0,2), in model 2.
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Figure 4.4: Mean posteriori probabilities of entering and leaving the epidemic in-
fluenza activity state according to the non-homogenous models (1 and 2).
Figure 4.5 depicts, for all the models, the weekly mean posterior probability of
being in the epidemic sate. This value is concentrated in the neighborhood of zero
or one, meaning that there is a low proportion of weeks with doubtful classification,
i.e. with the posterior mean probability of being in the epidemic state near 0.5.
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Concerning the classification of each week in the epidemic or in the non-epidemic
state, a week was considered as epidemic (non epidemic) if the posteriori probability
of belonging to the epidemic state was higher or equal to 0.5 (lower than 0.5). An
epidemic period was defined as the consecutive set of weeks with the mean posterior
probability of being in the epidemic state above 0.5.
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Figure 4.5: Panel 1: Mean posteriori probabilities of epidemic influenza activity
(Model 0: green; Model 1: red; Model 2: blue). Panel 2 : Influenza-like illness rates,
reported by Wednesday (solid line); periods of epidemic activity according to model
fitted and probability threshold of influenza epidemic activity (colored boxes).
The non homogenous models identified four epidemic periods in the study period
while the homogenous model identified three (Table 4.3). In Figure 4.5 it can be seen
that in season 2009-2010, that corresponds to the (H1N1)2009 pandemic in the period
from week 37/09 to week 2/10, the non homogenous models identified two distinct
epidemics but the homogenous one considered only one epidemic period that started
by week 37/09 and ended by week 53/09. On the other hand, the epidemic periods
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for seasons 2008-09 and 2009-10 were consistently estimated by the three models.
Season Model 0 Model 1 Model 2
2008-2009 48/08 to 7/09 48/08 to 8/09 47/08 to 8/09
2009-2010 37/09 to 53/10 37/09 to 39/09 37/09 to 39/09
42/09 to 01/09 42/09 to 02/10
2010-2011 46/10 to 10/11 46/10 to 10/11 46/10 to 10/11
Table 4.3: Estimated influenza epidemic periods by proposed models for a posterior
probability of being in the epidemic state higher than 0.5. Values represent week/year.
4.6.2 Real-time nowcast of 2010-11 influenza season
In Figure 4.6 the results of the weekly real-time influenza activity state nowcast and
decoding are presented for season 2010-11. In the first panel one can see the mean
posterior probability (mpp) of being in the epidemic state calculated in the same
week using equation 4.5. The second panel shows the weekly mpp of being in the
epidemic state calculated in the following week, i.e., with the ILI rate of the interest
week totally observed. Finally the last panel presents the weekly mpp of being in the
epidemic state calculated after all the ILI rate values for season 2010-11 are know,
i.e. by week 17/2011.
At the end of the season, by week 17/2011, all the three models define the epidemic
period from week 46/2010 to week 10/2011, presenting very similar epidemic state
mpp. In general, regarding the nowcasting and the decoding of the last ILI rate
observed, the non homogenous models presented an early increase and decrease in
the weekly epidemic state mpp, specially model 2.
If one considers 0.5 as the mpp cut-off value to classify a week in the epidemic
period, the first signal of the epidemic start is observed in week 48/2010 when model
2 decodes ILI rate of week 47/2010 as epidemic and nowcast for week 48/2010 a
epidemic state mpp very close to 0.5. This tendency continues to be observed in
week 49/2010, where model 2 calculates an epidemic state mpp in the neighborhood
of 0.5 for the observed week 48/2010 ILI rate and nowcast for that week (49/2010)
a epidemic state mpp clearly higher than 0.5. These results are then confirmed in
week 50/2011 by all the three models after week 49/2010 ILI rate became known.
It is important to underline that the non homogenous model 2 detects the signal of
epidemic start two week before the homogenous model. On the other hand, looking
for the signal of the end of the epidemic state, the non homogenous models also show
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Figure 4.6: Weekly mean posteriori probabilities of epidemic influenza activity (season
2010-11) calculated Panel 1: in the current week (nowcast); Panel 2: in the following
week; Panel 3: at end of the season. (.) week of the calculus.
better results, given that epidemic state mpp start to decrease earlier. Nevertheless
it is only by week 13/2011 that model 2 nowcasts the end of the epidemic, what
is confirmed in week 14/2011 when week 13/2011 ILI rate is finally known. The
homogenous model is clearly more slowly in entering and leaving the epidemic state,
which tends to increase the timeliness in detecting the epidemic start and end.
Furthermore the weekly ILI rates nowcasted by the three models (obtained by
equation 4.6) do not present relevant differences, although non homogenous models
present higher ILI rate estimates than the homogenous model. As can be seen in
Figure 4.7, weekly ILI rates of season 2010-11 were predicted during the same week
in a very satisfactory way, they start to increase, reached the peak and decrease in
synchrony. This means that the models were able to tackle the ILI rate evolution by
Friday of the same week, reducing reporting delay in 4 days.
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Figure 4.7: ILI rate nowcast for season 2010-11. (.) week of the calculus.
4.7 Discussion
Considering the main objective of this work, the models here proposed were able to
nowcast the ILI incidence rate and the influenza activity state by Friday of the same
week. These results were better achieved with the non homogenous HMM. As can
be seen in the previous section, the non homogenous models were able to nowcast
the beginning of the epidemic state two weeks before the homogenous model. On
the other hand at the end of the epidemic, the probability of being in the epidemic
state decreased more rapidly when calculated by the non homogenous models. Both
these results underline the adding value of using non homogenous HMM to nowcast
influenza epidemics. The inclusion of covariates, with early information on the epi-
demic evolution, to model the transition probabilities is of particulary importance
to empower the model in the nowcasting task. Actually, using a homogenous HMM
does not add too much to the nowcasting task given that the probability of a change
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is immutable in time.
Also important to notice is the fact that when the models were fitted to the entire
data set, the non homogenous models presented a better fit to the entire data set than
the homogenous models, and identified in season 2009-10 (the pandemic (H1N1)2009)
two distinct epidemic periods, where the homogenous model only identified one. Dur-
ing the 2009-10 influenza pandemic most of the European countries experienced two
epidemic waves, one during Summer and a second one during Autumn and Portugal
was an not exception. In fact, looking at other sources of information used during the
pandemic (H1N1)2009 (e.g National Network of Laboratories for the A(H1N1) Diag-
nostic) a first small epidemic wave was identified in the period from week 31/2009 to
week 39/2009 [107, 108]. All these features show that the non homogenous models
give more reliable results.
Comparing both non homogenous models, model 1 and 2, model 2 presented the
best results given that it produced the highest value of natural logarithm of the
marginal likelihood and showed the higher capacity to nowcast the epidemic start in
the real-time nowcast of season 2010-11.
Although these satisfactory results, the models proposed and data used have some
caveats that must be addressed.
First the models were build using some ad-hoc decisions, more precisely regarding
the structure of the state specific covariates used to model the response variable yt(t)0
and yt(t)1 and also when establishing, respectively a linear and quadratic relation
between this estimates and the reported ILI rate yt(t+1). In the first decision we set
the cut-offs at v0 = 1 and v1 = 20 based on the empirical knowledge of the surveillance
system. To evaluate the importance of this decision we have also fitted to all the data
set the homogenous model using other cut-off values for v1, more specifically 5 and
10, without substantial changes in the results. Nevertheless, when applying these
models to other surveillance systems, these fixed parameters should be tuned using
empirical knowledge or exploratory data analysis.
Regarding the decision to set the association of the early estimate of the ILI rate as
linear for the non epidemic state and quadratic for the epidemic state, other options,
namely linear-linear, were also tested for the homogenous models presenting worst
results, mainly in the real-time nowcast of the ILI rate.
Other point of interest, but that works against the non homogenous models, is
the higher number of iterations, burn-in and thinning needed for the model MCMC
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output to converge. This fact has particular impact in the computational time needed
to obtain the nowcast results each week. The main reason for this is that the covariates
transition probabilities parameters α are sampled using the random-walk Metropolis-
Hastings algorithm, and this algorithm has a slower convergence than the Gibbs
algorithm. In this study we have used a logistic function to model these probabilities,
which enable the direct sampling of α0,1 and α0,1 from the posterior full conditional
distribution. A possible further development for the proposed model could be to
choose a function to model the transition probabilities that could enable the use of
the Gibbs algorithm to sample their specific parameters. Nevertheless this fact does
not influence the timeliness of the nowcast objective, since the parameters estimation,
that is more time consuming, can be obtain previously (by Wednesday) and the
nowcast by Friday when the early estimate of the ILI rate is available.
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Chapter 5
Conclusions
Generally the main research objectives of this thesis were all achieved with consider-
able success.
Regarding the first objective, to unify in a single class the statistical methods,
characterized by using interrupted mortality time series to estimated excess deaths
attributable to influenza epidemics, in order to describe and compare their applica-
bility and results, the present work made possible to define a class of methods that
contains the principal models, without covariates, that use interrupted time series to
estimate influenza-associated deaths. They were categorized according to three main
parameters: the model used to fit the interrupted time series and obtain a baseline,
the a priori chosen type of periods used to estimate the influenza epidemic periods
and the type of procedure used to fit the model to the time series (iterative or non
iterative). This generalization led quite naturally to the construction of a set of user
friendly R-routines, package flubase, for estimating these influenza-associated deaths
with any of the methods in the class, that is available on the internet for download in
http://cran.r-project.org/web/packages/flubase/index.html [27]. As it was
developed, the flubase package can also be an important tool to compare the in-
fluenza associated deaths obtained by all the methods, just by varying each one of
the parameters involved, allowing the researcher to perform sensitivity or specificity
analysis of the obtained results.
Further, this package and methods framework has also shown to be useful to
estimate excesses of deaths attributable to other events defined in time and with
potential impact on the indicator of interest, e.g the excess deaths attributable to
heat-waves [45, 46]. In this situation the Ea period is set as the period where the
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heat-wave occurred.
The methods included in the framework were also applied to an example, the time
series of weekly mortality due to P&I in Portugal for the period of 1980 to 2004. The
results obtained suggest that:
1. In the absence of any reliable external source of information to define the epi-
demic periods (Ea) one should definitely choose the fixed period approach.
Nonetheless the estimation of the Ea periods with more informative sources,
leading to different Ea periods from year to year, is more desirable if one pre-
tends a more conservative approach. This last option might be preferable given
the evidence that: the duration and intensity of the influenza epidemics vary
widely from season to season [35]; extracting all winter mortality data means
that the baseline during these periods is estimated without any information
from them; and also because the ecological nature of this type of studies re-
quires precaution on the attribution of excess mortality to an event;
2. As it is known the seasonal ARIMA model is more adequate to model this type
of time dependent data, producing non autocorrelated residuals and leading to
a better estimate of the threshold, which is essential for the identification of
the periods with excess deaths attributable to influenza (Da). Given this, that
has already been stated by others [13], one can ask why the ARIMA models
are so rarely used. The answer might be that not only they are more difficult
to understand and apply, but also the graphical aspect of the resulting baseline
is not as smooth as the sinusoidal curve of the cyclic regression model. Actu-
ally, this visual characteristic has already been suggested to be a reason why
government agencies (e.g US CDC) have chosen the regression approach [19] to
estimate influenza associated deaths;
3. The iterative procedure should only be used for stationary time series, naturally
leading to baselines further apart from the observed in those periods where a
change in trend occurs, even with a very mild tendency as our application shows.
When a serious lack of stationarity occurs the usual correction measures should
be previously applied. Nonetheless it seems important to say that when the
objective is to define a baseline for prospective identification and estimation of
excess deaths in a mortality surveillance framework, this kind of methods are
more useful [8, 9, 13, 48, 45].
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The first objective did not include the study of the second group of methods
used to estimate excess deaths attributable to influenza. This group is characterized
by including in the model, to be adjusted to the time series mortality, an influenza
activity indicator, like ILI incidence rates or number of influenza laboratory confirmed
cases. Although some works have been presented where this models are compared
with others [109], we considered that at this moment there is not yet a study that
unify and describe this group of methods in a single class allowing a proper platform
to compare them. This should be in our opinion one possible further work to be
developed in this area.
Considering the second objective, to estimate the excess mortality associated
with the influenza epidemics occurred in Portugal in the period from 1980 to 2004
and compare the results with those from other locations, the present study shows
that in the period from 1980 to 2004, the seasonal average number of all cause excess
deaths associated with influenza epidemics was 2,475 in Portugal, representing a crude
excess all-cause death rate of 24.7 per 100,000 inhabitants. These seasonal influenza
associated excess deaths ranged from 0, in five out of the 24 study seasons, to 8,514 in
1998-1999 season. Another important result was that in average 90% of the estimated
excess deaths attributable to influenza occurred in people aged ≥ 65 years. All these
results suggest that influenza epidemics in Portugal had in general the same profile
as that described for other temperate countries in the Northern Hemisphere.
This is the first study to provide estimates of influenza seasonal mortality burden
in the Portuguese population in a comprehensive way, an important step to set up
references to contextualize the severity of the forthcoming influenza epidemics, but
also for the design of rational national public health measures to mitigate influenza
epidemics impacts.
A few issues could be further explored, in particular the potentially higher mortal-
ity burden in extreme age groups (0-4 and ≥ 65), compared to other countries. As in
other countries, population ageing tends to increase the absolute burden of influenza,
which has important consequences for disease control and public health strategies.
Another important point to note is the fact that the impact of influenza epidemics in
Portugal was relatively well captured in the all-cause mortality time series. This result
supports the use of this indicator for influenza surveillance purposes in Portugal, in
particular to give near real-time estimates of inter-pandemic and pandemic influenza
mortality impact [45, 46, 5]. We note that all-cause mortality is less dependent on
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diagnostic and coding differences between countries, time periods, or during unusual
events like pandemics, as compared with cause-specific indicators. Further studies
in other settings are warranted to confirm that all-cause mortality is an appropriate
indicator to compare the impact of influenza epidemics at a regional and global scale
[16, 110, 111].
Regarding the third objective, to develop a statistical model to nowcast an in-
fluenza epidemic evolution the work presented shows the advantage of using a non
homogenous HMM to nowcast the ILI incidence rate and the influenza activity state
in the context of a public health surveillance system. This advantage is achieved given
that the non homogenous HMM enables the inclusion of covariates, with early infor-
mation on the epidemic evolution, to model the influenza activity states transition
probabilities. This feature has been shown to be of particular importance to empower
the model in the nowcast task, mainly in comparison with the homogenous HMM,
previously used in the literature, that does not add too much to the nowcasting task
because the state transition probabilities are the same for all moments in time.
This thesis have also demonstrated that in Portuguese surveillance system the
incomplete information from a GP based influenza surveillance enabled the early
detection of the epidemic start. More specifically, it was possible to show that using
a non homogenous HMM, with an early estimated of the ILI rate by Friday of the
same week, improved the surveillance system timeliness in 2 weeks.
Since the proposed models were fitted to data that corresponds to three influenza
seasons of the Portuguese ISS, and the real-time nowcast simulation was tested in
one influenza season (2010-11), it is important to state that further applications of
these models, to a higher number of seasons and also to data from other public health
surveillance systems, are needed in order to warrant the adding value of using non
homogenous HMMs to nowcast an epidemic evolution in the public health surveillance
setting.
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104 A. SARIMA best-fitted models
Outcome Model Box-Ljung test for auto-correlation of residuals
All causes
0-4 ARIMA(0,1, 2)(1, 0, 1)12 X = 2.5754, df = 5.663, p = 0.8321
5-54 ARIMA(2,1, 1)(2, 0, 2)12 X = 3.2763, df = 5.663, p = 0.7379
55-64 ARIMA(2,1, 2)(1, 0, 1)12 X = 4.3128, df = 5.663, p = 0.5929
65-69 ARIMA(1,1, 2)(2, 0, 1)12 X = 3.4083, df = 5.663, p = 0.7194
70-74 ARIMA(4,1, 2)(2, 0, 1)12 X = 1.1144, df = 5.663, p = 0.9739
75-79 ARIMA(2,1, 1)(2, 0, 0)12 X = 6.3192, df = 5.663, p = 0.34
80-84 ARIMA(1,1, 2)(2, 0, 1)12 X = 2.9072, df = 5.663, p = 0.7886
≥ 85 ARIMA(1,1, 1)(2, 0, 1)12 X = 6.7818, df = 5.663, p = 0.3053
Diseases of respiratory system
0-4 ARIMA(1,1, 2)(1, 0, 1)12 X = 0.201, df = 5.663, p = 0.9997
5-54 ARIMA(2,1, 1)(0, 0, 2)12 X = 4.3446, df = 5.663, p = 0.5885
55-64 ARIMA(0,1, 3)(0, 0, 2)12 X = 8.1654, df = 5.663, p = 0.1979
65-69 ARIMA(1,1, 1)(2, 0, 0)12 X = 4.356, df = 5.663, p = 0.5869
70-74 ARIMA(2,1, 1)(2, 0, 1)12 X = 1.5089, df = 5.663, p = 0.9465
75-79 ARIMA(1,0, 0)(2, 0, 2)12 X = 2.429, df = 5.663, p = 0.8504
80-84 ARIMA(1,1, 1)(1, 0, 1)12 X = 2.5779, df = 5.663, p = 0.8318
≥ 85 ARIMA(5,1, 3)(2, 0, 1)12 X = 0.7527, df = 5.663, p = 0.9902
Chronic respiratory diseases
0-4 ARIMA(0,1, 1)(1, 0, 0)12 X = 8.7101, df = 5.663, p = 0.1654
5-54 ARIMA(1,1, 1)(0, 0, 2)12 X = 7.2876, df = 5.663, p = 0.26
55-64 ARIMA(2,1, 2)(1, 0, 1)12 X = 4.8272, df = 5.663, p = 0.5239
65-69 ARIMA(0,1, 4)(0, 0, 2)12 X = 5.4006, df = 5.663, p = 0.451
70-74 ARIMA(1,1, 0)(2, 0, 1)12 X = 29.0582, df = 5.663, p < 0.001
75-79 ARIMA(4,1, 1)(2, 0, 1)12 X = 4.0111, df = 5.663, p = 0.6347
80-84 ARIMA(2,1, 1)(2, 0, 1)12 X = 2.4044, df = 5.663, p = 0.8535
≥ 85 ARIMA(3,0, 4)(1, 0, 1)12 X = 2.917, df = 5.663, p = 0.787
Pneumonia and Influenza
0-4 ARIMA(3, 1, 3) X = 1.6593, df = 5.663, p = 0.9336
5-54 ARIMA(2,0, 1)(0, 0, 1)12 X = 3.4964, df = 5.663, p = 0.707
55-64 ARIMA(2,0, 1)(1, 0, 1)12 X = 6.496, df = 5.663, p = 0.332
65-69 ARIMA(2,0, 1)(2, 0, 2)12 X = 4.8612, df = 5.663, p = 0.5194
70-74 ARIMA(3,0, 3)(2, 0, 2)12 X = 1.7874, df = 5.663, p = 0.9216
75-79 ARIMA(1,0, 2)(2, 0, 2)12 X = 1.7948, df = 5.663, p = 0.9209
80-84 ARIMA(2,1, 1)(2, 0, 2)12 X = 2.6166, df = 5.663, p = 0.8268
≥ 85 ARIMA(0,1, 1)(1, 0, 1)12 X = 1.2253, df = 5.663, p = 0.9672
Cardiovascular disease
0-4 ARIMA(1,0, 1)(1, 0, 1)12 X = 9.8662, df = 5.663, p = 0.1114
5-54 ARIMA(0,1, 2)(1, 0, 2)12 X = 5.4022, df = 5.663, p = 0.4516
55-64 ARIMA(2,1, 2)(1, 0, 1)12 X = 1.003, df = 5.663, p = 0.9798
65-69 ARIMA(1,1, 1)(2, 0, 1)12 X = 3.9818, df = 5.663, p = 0.6388
70-74 ARIMA(3,1, 1)(2, 0, 2)12 X = 1.0118, df = 5.663, p = 0.9794
75-79 ARIMA(3,1, 3)(1, 0, 1)12 X = 0.1189, df = 5.663, p = 1
80-84 ARIMA(2,1, 1)(2, 0, 2)12 X = 4.2804, df = 5.663, p = 0.5973
≥ 85 ARIMA(1,1, 2)(2, 0, 0)12 X = 0.3565, df = 5.663, p = 0.9986
Ischemic heart disease
0-4 ARIMA(0,1, 1)(1, 0, 0)12 X = 2.3994, df = 5.663, p = 0.854
5-54 ARIMA(1,1, 2)(2, 0, 1)12 X = 1.236, df = 5.663, p = 0.9665
55-64 ARIMA(2,1, 3)(1, 0, 2)12 X = 1.5871, df = 5.663, p = 0.94
65-69 ARIMA(4,1, 3)(1, 0, 1)12 X = 1.4818, df = 5.663, p = 0.9487
70-74 ARIMA(2,1, 1)(2, 0, 2)12 X = 0.9129, df = 5.663, p = 0.984
75-79 ARIMA(2,1, 1)(1, 0, 2)12 X = 5.2412, df = 5.663, p = 0.4713
80-84 ARIMA(1,1, 0)(1, 0, 1)12 X = 35.1582, df = 5.663, p < 0.001
≥ 85 ARIMA(2,0, 4)(0, 0, 1)12 X = 1.343, df = 5.663, p = 0.9592
Table A.1: Seasonal ARIMA best-fitted models by R package forecast and Box-Ljong
test for residuals auto correlation
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Figure A.1: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 0-4
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Figure A.2: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 5-54
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Figure A.3: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 55-64
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Figure A.4: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 65-69
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Figure A.5: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 70-74
110
A
.
S
A
R
IM
A
b
est-fi
tted
m
o
d
els
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
4
0
0
A. All cause mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
1
5
0
B. Cerebrovascular diseases mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
4
0
8
0
C. Ischemic heart disease mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
4
0
1
0
0
D. Respiratory diseases mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
2
0
4
0
E. Chronic respiratory diseases mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
2
0
4
0
F. Pneumonia and influenza mortality
m
o
r
t
a
l
i
t
y
1980 1985 1990 1995 2000 2005
0
1
0
2
5
G. All injuries mortality
Figure A.6: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 75-79
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Figure A.7: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group 80-84
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Figure A.8: Mortality rates (blue), mortality baseline (black) and 95% confidence limit (red), estimated excess death rate
(green) by month and influenza epidemic periods (grey rectangles) for the study causes of death - age group ≥ 85
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114 B. Sensitivity analysis
Season
Excess
(absolute number)
Age-standardized
excess rate 105
Proportion of
excess (oct-may) All external
All external
rate
1980/1981 47 0.40 1.0% 4547 42.1
1981/1982 30 0.20 0.5% 4783 44.2
1982/1983 15 0.12 0.3% 4650 42.0
1983/1984 29 0.15 0.4% 4628 41.6
1984/1985 0 0.00 0.0% 4472 39.7
1985/1986 16 0.08 0.2% 4265 37.4
1986/1987 15 0.07 0.2% 4461 39.4
1987/1988 0 0.00 0.0% 4420 42.1
1988/1989 15 0.09 0.2% 4393 44.2
1989/1990 32 0.23 0.7% 4097 42.0
1990/1991 30 0.31 0.8% 4255 41.6
1991/1992 0 0.00 0.0% 4338 39.7
1992/1993 0 0.00 0.0% 4059 37.4
1993/1994 0 0.00 0.0% 3672 39.4
1994/1995 0 0.00 0.0% 3654 42.1
1995/1996 30 0.16 0.5% 3655 44.2
1996/1997 18 0.12 0.4% 3590 42.0
1997/1998 18 0.11 0.4% 3509 41.6
1998/1999 37 0.14 0.5% 3318 39.7
1999/2000 27 0.19 0.8% 3199 37.4
2000/2001 0 0.00 0.0% 3055 39.4
2001/2002 277 2.56 8.4% 3865 42.1
2002/2003 26 0.17 0.6% 3684 44.2
2003/2004 0 0.00 0.0% 3518 42.0
Mean 28 0.21 0.66% 4004 41.2
Table B.1: Sensitivity analysis: excess deaths and age-standardized excess death
rates from injuries that are ”attributable to influenza” by the used method. Injuries
comprise all external causes of death.
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Figure C.1: Trace, autocorrelation function, histogram and density of τ0 parameter of model 0
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Figure C.2: Trace, autocorrelation function, histogram and density of τ1 parameter of model 0
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Figure C.3: Trace, autocorrelation function, histogram and density of µ parameter of model 0
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Figure C.4: Trace, autocorrelation function, histogram and density of β1 parameter of model 0
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Figure C.5: Trace, autocorrelation function, histogram and density of β2 parameter of model 0
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Figure C.6: Trace, autocorrelation function, histogram and density of θ0 parameter of model 0
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Figure C.7: Trace, autocorrelation function, histogram and density of θ1,1 parameter of model 0
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Figure C.8: Trace, autocorrelation function, histogram and density of θ1,2 parameter of model 0
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Figure C.9: Trace, autocorrelation function, histogram and density of γ0,0 parameter of model 0
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Figure C.10: Trace, autocorrelation function, histogram and density of γ0,1 parameter of model 0
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Figure C.11: Trace, autocorrelation function, histogram and density of γ1,0 parameter of model 0
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Figure C.12: Trace, autocorrelation function, histogram and density of γ1,1 parameter of model 0
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Figure C.13: Trace, autocorrelation function, histogram and density of τ0 parameter of model 1
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Figure C.14: Trace, autocorrelation function, histogram and density of τ1 parameter of model 1
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Figure C.15: Trace, autocorrelation function, histogram and density of µ parameter of model 1
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Figure C.16: Trace, autocorrelation function, histogram and density of β1 parameter of model 1
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Figure C.17: Trace, autocorrelation function, histogram and density of β2 parameter of model 1
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Figure C.18: Trace, autocorrelation function, histogram and density of θ0 parameter of model 1
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Figure C.19: Trace, autocorrelation function, histogram and density of θ1,1 parameter of model 1
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Figure C.20: Trace, autocorrelation function, histogram and density of θ1,2 parameter of model 1
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Figure C.21: Trace, autocorrelation function, histogram and density of α0,0 parameter of model 1
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Figure C.22: Trace, autocorrelation function, histogram and density of α0,1 parameter of model 1
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Figure C.23: Trace, autocorrelation function, histogram and density of α1,0 parameter of model 1
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Figure C.24: Trace, autocorrelation function, histogram and density of α1,1 parameter of model 1
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Figure C.25: Trace, autocorrelation function, histogram and density of τ0 parameter of model 2
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Figure C.26: Trace, autocorrelation function, histogram and density of τ1 parameter of model 2
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Figure C.27: Trace, autocorrelation function, histogram and density of µ parameter of model 2
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Figure C.28: Trace, autocorrelation function, histogram and density of β1 parameter of model 2
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Figure C.29: Trace, autocorrelation function, histogram and density of β2 parameter of model 2
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Figure C.30: Trace, autocorrelation function, histogram and density of θ0 parameter of model 2
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Figure C.31: Trace, autocorrelation function, histogram and density of θ1,1 parameter of model 2
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Figure C.32: Trace, autocorrelation function, histogram and density of θ1,2 parameter of model 2
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Figure C.33: Trace, autocorrelation function, histogram and density of α0,0 parameter of model 2
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Figure C.34: Trace, autocorrelation function, histogram and density of α0,1 parameter of model 2
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Figure C.35: Trace, autocorrelation function, histogram and density of α0,2 parameter of model 2
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Figure C.36: Trace, autocorrelation function, histogram and density of α1,0 parameter of model 2
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Figure C.37: Trace, autocorrelation function, histogram and density of α1,1 parameter of model 2
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Figure C.38: Trace, autocorrelation function, histogram and density of α1,2 parameter of model 2
